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Abstract: 1 SUMMARY In industrialized countries the incidence of Crohn’s disease (CD) and ulcera-
tive colitis (UC), the most common variants of inflammatory bowel diseases (IBD), is rising since the
beginning of the 20th century. IBD is believed to be caused by an overreacting immune response to-
wards otherwise commensal bacteria of the gut in genetical predisposed individuals, leading to chronic
intestinal inflammation. Genome wide association studies identified more than 160 genetic risk factors
that mediate IBD susceptibility indicating that IBD is a polygenetic disease. The gene encoding protein
tyrosine phosphatase non-receptor type 2 (PTPN2) is one of these risk genes identified so far. PTPN2
is also involved in the predisposition to other autoimmune diseases such as rheumatoid arthritis and
diabetes type 1. Colon specimens of IBD patients show increased levels of PTPN2 protein. Furthermore,
cell culture experiments proved that loss of PTPN2 in intestinal epithelia cells has detrimental effects on
important cellular processes, that are known to be involved in IBD pathogenesis including autophagy,
barrier function, and cytokine secretion. One aim of this thesis was to examine the role of PTPN2 in
the context of endoplasmic reticulum (ER) stress conditions. ER stress pathways are initiated upon
accumulation of misfolded proteins in the ER lumen and malfunction of these pathways are important
for the development of IBD. We used monocytes (THP-1) and colon epithelia cells (HT-29) which re-
sponded differently to siRNA mediated PTPN2 depletion. Whereas PTPN2 lacking monocytes became
more susceptible to tunicamycin induced ER stress, the absence of this phosphatase had beneficial effects
on colon epithelia cells. This clearly showed the cell type specific role of PTPN2 under ER stress condi-
tions. Another objective of this thesis was to investigate the role of PTPN2 in intestinal epithelia cells
in vivo. Therefore, we bred mice with a tissue specific knockout of PTPN2 in the intestinal epithelium
(PTPN2xVilCre mice) and induced colitis by dextran sodium sulfate (DSS) treatment. In the setup of
acute colitis, colonoscopy indicated more severe inflammation in PTPN2xVilCre animals compared to
their wild type littermates. Moreover, endoscopic control after chronic colitis suggested a less severe
inflammation in mice carrying the tissue specific knockout. These findings could not be confirmed by
histological analysis of colon specimens. Nevertheless, aberrant crypt foci were observed more frequently
in PTPN2 deficient mice, suggesting an increased susceptibility to colon cancer. In the azoxymethane
(AOM)/DSS model nearly all animals developed aberrant crypt foci irrespective of genotypes. Hence,
in colon epithelial cells PTPN2 plays only a minor role in inflammatory processes, suggesting that the
organism is capable of compensating this shortcoming. In summary, PTPN2 seems to be less crucial
for intestinal epithelial cells compared to monocytes. Given that the highest PTPN2 expression is found
in hematopoietic cells, this is not surprising. As shown by other studies, loss of PTPN2 in cells of the
immune system results in severe phenotypes. Here, we demonstrate that its loss in intestinal epithelial
cells can be compensated in vivo even during intestinal inflammation. 2 ZUSAMMENFASSUNG Chro-
nisch entzündliche Darmerkrankungen (CED) mit den beiden wichtigsten Varianten Morbus Crohn und
Colitis ulcerosa treten seit Beginn des 20. Jahrhunderts vor allem in industrialisierten Ländern vermehrt
auf. Bei diesen Erkrankungen handelt es sich um eine Überreaktion des Immunsystems gegenüber der
normalen Darmflora in genetisch veranlagten Personen, welche zur chronischen Entzündung des Darms
führen kann. Genomweite Assoziationsstudien haben bereits mehr als 160 genetische Risikofaktoren iden-
tifiziert, die zur Prädisposition beitragen. Unter diesen Risikogenen ist auch das Gen, welche die Protein
Tyrosin Phosphatase Non-Rezeptor Typ 2 (PTPN2) kodiert. PTPN2 vermittelt auch eine Neigung zur
Ausbildung anderer Immunkrankheiten wie rheumatoide Arthritis und Diabetes Typ 1 vermittelt. In
Darmbiopsien von CED Patienten findet man eine erhöhte Menge an PTPN2 Protein. Außerdem konnten
Experimente in Zellkultur bereits belegen, dass sich in Darmepithelzellen ein Fehlen von PTPN2 negativ
auf viele zelluläre Prozesse wie Autophagie, Barriere-Funktion und Zytokin-Ausschüttung auswirkt. Von
all diesen Prozessen weiß man, dass sie bei CED eine wichtige Rolle spielen. Ein Ziel dieser Arbeit war es,
die Rolle von PTPN2 im Zusammenhang mit endoplasmatischem Retikulum (ER) Stress zu untersuchen.
ER Stress Signalwege werden durch ein Anhäufung von falsch gefalteten Proteinen im Inneren des ER
ausgelöst und Fehlfunktionen innerhalb dieser Signalwege sind für die CED Pathogenese von Bedeutung.
Wir haben Experimente mit Monozyten (THP-1) und Darmepithelzellen (HT-29) durchgeführt, die beide
sehr unterschiedlich auf den siRNA vermittelten Verlust von PTPN2 reagierten. Während Monozyten
mit PTPN2 Defizit anfälliger für Tunicamyin induzierten ER Stress wurden, hatte der Verlust positive
Konsequenzen für Darmepithelzellen. Dies zeigt klar die Zelltyp spezifische Rolle dieser Phosphatase
im Kontext von ER Stress. Als weiteres Ziel sollte im Rahmen dieser Promotionsarbeit die Bedeu-
tung von PTPN2 für Darmepithelzellen in vivo untersucht werden. Dazu wurden Mäuse gezüchtet, die
im Darmepithel kein PTPN2 exprimieren (PTPN2xVilCre Mäuse) und diesen durch Verabreichung von
Dextran Natriumsulfat (DSS) eine Kolitis induziert. Die Koloskopie nach einer akuten DSS Kolitis gab
Hinweise auf eine gesteigerte Entzündung bei PTPN2xVilCre Tieren im Vergleich zu ihren wildtypischen
Wurfgeschwistern. Die endoskopische Kontrolle nach der chronischen DSS Kolitis zeigte hingegen eine
mildere Entzündung in den Tieren mit gewebespezifischem knockout. Histologischen Untersuchungen von
Darmbiopsien konnten diese Unterschiede jedoch nicht bestätigen. Allerdings beobachteten wir vermehrt
abnorme Krypten in PTPN2 defizienten Mäusen bei der chronischen DSS Kolitis. Dies ließ uns zunächst
vermuten, dass in diesen Tiere ein erhöhtes Risiko für kolorektale Karzinome vorliegt. Die Kombina-
tion von Azoxymethan (AOM) Injektion und DSS Gabe konnte diese These jedoch nicht bestätigen, da
nahezu alle Tiere unabhängig von ihrem Genotyp abnorme Krypten ausbildeten. In Darmepithelzellen
spielt PTPN2 daher keine relevante Rolle für den Entzündungsprozess, der Mangel kann durch den Or-
ganismus offensichtlich kompensiert werden. PTPN2 scheint also in Darmepithelzellen weniger wichtig
zu sein als in Monozyten. Dies ist nicht sonderlich überraschend, wenn man bedenkt, dass die höch-
ste PTPN2 Expression bekanntermaßen in blutbildenden Zellen zu finden ist. Andere Studien konnten
bereits zeigen, dass ein Verlust der PTPN2 Expression in Immunzellen in starken Phänotypen resultiert.
Wir zeigen hier, dass ein PTPN2 Defizit in Darmepithelzellen auch während einer Entzündung in vivo
kompensiert werden kann.
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2 SUMMARY 
In industrialized countries the incidence of Crohn’s disease (CD) and ulcerative 
colitis (UC), the most common variants of inflammatory bowel diseases (IBD), is 
rising since the beginning of the 20th century. IBD is believed to be caused by an 
overreacting immune response towards otherwise commensal bacteria of the gut 
in genetical predisposed individuals, leading to chronic intestinal inflammation. 
Genome wide association studies identified more than 160 genetic risk factors 
that mediate IBD susceptibility indicating that IBD is a polygenetic disease. The 
gene encoding protein tyrosine phosphatase non-receptor type 2 (PTPN2) is one 
of these risk genes identified so far. PTPN2 is also involved in the predisposition 
to other autoimmune diseases such as rheumatoid arthritis and diabetes type 1. 
Colon specimens of IBD patients show increased levels of PTPN2 protein. 
Furthermore, cell culture experiments proved that loss of PTPN2 in intestinal 
epithelia cells has detrimental effects on important cellular processes, that are 
known to be involved in IBD pathogenesis including autophagy, barrier function, 
and cytokine secretion. 
One aim of this thesis was to examine the role of PTPN2 in the context of 
endoplasmic reticulum (ER) stress conditions. ER stress pathways are initiated 
upon accumulation of misfolded proteins in the ER lumen and malfunction of 
these pathways are important for the development of IBD. We used monocytes 
(THP-1) and colon epithelia cells (HT-29) which responded differently to siRNA 
mediated PTPN2 depletion. Whereas PTPN2 lacking monocytes became more 
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susceptible to tunicamycin induced ER stress, the absence of this phosphatase 
had beneficial effects on colon epithelia cells. This clearly showed the cell type 
specific role of PTPN2 under ER stress conditions. 
Another objective of this thesis was to investigate the role of PTPN2 in intestinal 
epithelia cells in vivo. Therefore, we bred mice with a tissue specific knockout of 
PTPN2 in the intestinal epithelium (PTPN2xVilCre mice) and induced colitis by 
dextran sodium sulfate (DSS) treatment. In the setup of acute colitis, 
colonoscopy indicated more severe inflammation in PTPN2xVilCre animals 
compared to their wild type littermates. Moreover, endoscopic control after 
chronic colitis suggested a less severe inflammation in mice carrying the tissue 
specific knockout. These findings could not be confirmed by histological analysis 
of colon specimens. Nevertheless, aberrant crypt foci were observed more 
frequently in PTPN2 deficient mice, suggesting an increased susceptibility to 
colon cancer. In the azoxymethane (AOM)/DSS model nearly all animals 
developed aberrant crypt foci irrespective of genotypes. Hence, in colon 
epithelial cells PTPN2 plays only a minor role in inflammatory processes, 
suggesting that the organism is capable of compensating this shortcoming. 
In summary, PTPN2 seems to be less crucial for intestinal epithelial cells 
compared to monocytes. Given that the highest PTPN2 expression is found in 
hematopoietic cells, this is not surprising. As shown by other studies, loss of 
PTPN2 in cells of the immune system results in severe phenotypes. Here, we 
demonstrate that its loss in intestinal epithelial cells can be compensated in vivo 
even during intestinal inflammation.  
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3 ZUSAMMENFASSUNG 
Chronisch entzündliche Darmerkrankungen (CED) mit den beiden wichtigsten 
Varianten Morbus Crohn und Colitis ulcerosa treten seit Beginn des 
20. Jahrhunderts vor allem in industrialisierten Ländern vermehrt auf. Bei diesen 
Erkrankungen handelt es sich um eine Überreaktion des Immunsystems 
gegenüber der normalen Darmflora in genetisch veranlagten Personen, welche 
zur chronischen Entzündung des Darms führen kann. Genomweite 
Assoziationsstudien haben bereits mehr als 160 genetische Risikofaktoren 
identifiziert, die zur Prädisposition beitragen. Unter diesen Risikogenen ist auch 
das Gen, welche die Protein Tyrosin Phosphatase Non-Rezeptor Typ 2 (PTPN2) 
kodiert. PTPN2 vermittelt auch eine Neigung zur Ausbildung anderer 
Immunkrankheiten wie rheumatoide Arthritis und Diabetes Typ 1 vermittelt.  
In Darmbiopsien von CED Patienten findet man eine erhöhte Menge an PTPN2 
Protein. Außerdem konnten Experimente in Zellkultur bereits belegen, dass sich 
in Darmepithelzellen ein Fehlen von PTPN2 negativ auf viele zelluläre Prozesse 
wie Autophagie, Barriere-Funktion und Zytokin-Ausschüttung auswirkt. Von all 
diesen Prozessen weiß man, dass sie bei CED eine wichtige Rolle spielen. 
Ein Ziel dieser Arbeit war es, die Rolle von PTPN2 im Zusammenhang mit 
endoplasmatischem Retikulum (ER) Stress zu untersuchen. ER Stress 
Signalwege werden durch ein Anhäufung von falsch gefalteten Proteinen im 
Inneren des ER ausgelöst und Fehlfunktionen innerhalb dieser Signalwege sind 
für die CED Pathogenese von Bedeutung. Wir haben Experimente mit 
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Monozyten (THP-1) und Darmepithelzellen (HT-29) durchgeführt, die beide sehr 
unterschiedlich auf den siRNA vermittelten Verlust von PTPN2 reagierten. 
Während Monozyten mit PTPN2 Defizit anfälliger für Tunicamyin induzierten ER 
Stress wurden, hatte der Verlust positive Konsequenzen für Darmepithelzellen. 
Dies zeigt klar die Zelltyp spezifische Rolle dieser Phosphatase im Kontext von 
ER Stress. 
 Als weiteres Ziel sollte im Rahmen dieser Promotionsarbeit die Bedeutung von 
PTPN2 für Darmepithelzellen in vivo untersucht werden. Dazu wurden Mäuse 
gezüchtet, die im Darmepithel kein PTPN2 exprimieren (PTPN2xVilCre Mäuse) 
und diesen durch Verabreichung von Dextran Natriumsulfat (DSS) eine Kolitis 
induziert. Die Koloskopie nach einer akuten DSS Kolitis gab Hinweise auf eine 
gesteigerte Entzündung bei PTPN2xVilCre Tieren im Vergleich zu ihren 
wildtypischen Wurfgeschwistern. Die endoskopische  Kontrolle nach der 
chronischen DSS Kolitis zeigte hingegen eine mildere Entzündung in den Tieren 
mit gewebespezifischem knockout. Histologischen Untersuchungen von 
Darmbiopsien konnten diese Unterschiede jedoch nicht bestätigen. Allerdings 
beobachteten wir vermehrt abnorme Krypten in PTPN2 defizienten Mäusen bei 
der chronischen DSS Kolitis. Dies ließ uns zunächst vermuten, dass in diesen 
Tiere ein erhöhtes Risiko für kolorektale Karzinome vorliegt. Die Kombination 
von Azoxymethan (AOM) Injektion und DSS Gabe konnte diese These jedoch 
nicht bestätigen, da nahezu alle Tiere unabhängig von ihrem Genotyp abnorme 
Krypten ausbildeten. In Darmepithelzellen spielt PTPN2 daher keine relevante 
Rolle für den Entzündungsprozess, der Mangel kann durch den Organismus 
offensichtlich kompensiert werden. 
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PTPN2 scheint also in Darmepithelzellen weniger wichtig zu sein als in 
Monozyten. Dies ist nicht sonderlich überraschend, wenn man bedenkt, dass die 
höchste PTPN2 Expression bekanntermaßen in blutbildenden Zellen zu finden 
ist. Andere Studien konnten bereits zeigen, dass ein Verlust der PTPN2 
Expression in Immunzellen in starken Phänotypen resultiert. Wir zeigen hier, 
dass ein PTPN2 Defizit in Darmepithelzellen auch während einer Entzündung in 
vivo kompensiert werden kann. 
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4 INTRODUCTION 
4.1 The human gastrointestinal tract 
The human gastrointestinal tract (GI tract) is a tubular organ system reaching 
from mouth to anus. Its purpose is the digestion of food thereby absorbing 
nutrients to provide the body with energy. The indigestible remains are expelled 
as faeces. The whole human GI tract is about 9 m long. The transit time varies 
greatly and depends on the type of food and the amount of fluid intake and is 
individually different. 
After mechanical crushing and moistening the food leaves the oral cavity and 
enters the stomach via oesophagus. In the stomach food is stored temporarily 
and mixed with mucus and gastric juice. The gastric glands produce about 
2500 ml gastric juice every day, which contains digestion enzymes, hydrochloric 
acid, potassium chloride and sodium chloride. The low pH of 1.5 to 2 causes the 
death of most of the microbes in our food and provides the optimal conditions for 
pepsin, a digestive enzyme that degrades proteins. The stomach capacity varies 
between individuals, but is on average about 1.5 l. Peristaltic movement 
forwards the semi fluid mass to the duodenum2. 
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The duodenum forms a C-shaped connection between the stomach and the 
small intestine (cf. Figure 4-1). Pancreas, liver and gallbladder assist in 
digestion by secreting enzymes, bile and hormones into the duodenum. Bile, 
which is produced in the liver and stored in the pancreas, functions as emulsifier 
thereby degrading lipids. The Brunner’s glands of the duodenal mucosa release 
alkaline mucus containing a lot of bicarbonate to neutralize the acid pH of the 
chyme.  
The rest of the small intestine is sectioned into jejunum and ileum but this 
distinction is artificial, having no clear anatomical border (cf. Figure 4-1). The 
upper 2/5 part is defined as jejunum and the lower 3/5 section is called ileum, 
while both parts together are about 5-7 m in length. Even though there is a 
smooth transition between jejunum and ileum, there are microscopic anatomical 
differences between the proximal start of the jejunum and the distal end of the 
ileum. In the duodenum and proximal jejunum the mucosa forms tall circular 
folds (plicae) and possess many villi standing close together. In the distal part of 
the ileum the plicae are more separated from each other and there is an 
increased occurrence of solitary lymph nodules within the mucosa.  
The majority of fluid and nutrient absorption takes place in the small intestine3. 
Peristaltic movement of the smooth muscles within the small intestinal wall 
pushes the chyme into the large intestine. 
  
INTRODUCTION 
 
17 
  
Figure 4-1 Structure of the gastrointestinal tract (image source: 
adapted from1). Ingested food enters the stomach via esophagus. The 
small intestine is subdivided into duodenum, jejunum, and ileum. From 
the large intestine only the colon is shown. 
The human gastrointestinal tract 
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4.1.1 The colon – general function and microscopic architecture 
The large intestine is divided into cecum, colon, rectum and anal canal. The 
cecum is a dead-end pouch between ileum and colon. The cecum of herbivores 
is enlarged and contains many bacteria that aid in digestion of cellulose. 
 In the colon, complex carbohydrates and also some proteins can be fermented 
by the huge population of bacteria that reside here4. Humans live in a symbiotic 
relationship with the myriads of bacteria that form our gut microbiota and 
produce short-chain fatty acids from otherwise indigestive food residues. The 
salvaged nutrients are then absorbed by intestinal enterocytes, the cell type that 
is also responsible for water homeostasis. The colon is substantial for water 
absorption, thereby producing about 200 g solid stool per day5. In contrast to the 
small intestine, the colon mucosa does not form villi. Peristaltic movements, 
created by the circular muscles in the colon wall, force the faeces through the 
colon to the rectum. Here it is stored before defecation takes place through the 
anus. 
The colon wall is built of three layers: the muscularis externa, submucosa and 
mucosa (cf. Figure 4-2). As the most outer layer, the muscularis externa is 
embedded in loose connective tissue that holds the colon in its place within the 
peritoneal cavity. The muscularis externa consists of an inner circular and an 
outer longitudinal smooth muscle layer and is important for peristaltic movement. 
The submucosa is rich in blood and lymphatic vessels, nerve fibers and 
collagen fibrils that supply the mucosa. The mucosa represents the most inner 
layer and contains all the different cell types that are important for colon function 
and homeostasis.  
INTRODUCTION 
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The mucosa is further subdivided into three layers: the epithelium, lamina 
propria and muscularis mucosae (cf. Figure 4-2).  
A single layer of epithelial cells separates our gut tissue (and subsequently our 
body) from the environment. The epithelium forms a physical and chemical 
barrier and can interact with commensals and pathogens (cf. chapter 4.1.3). The 
inner surface of the colon is enlarged by gland-like infoldings, the crypts of 
Lieberkühn. These crypts are covered by epithelium, which contains multiple cell 
types: enterocytes (water and electrolyte absorption), goblet cells (mucus 
secretion), enteroendocrine cells (hormone secretion), and stem cells.  
The pluripotent intestinal stem cells reside at the crypt base and give rise to all 
epithelial cell types. The colon epithelium is highly proliferating, leading to a 
complete turnover every 24-96 hours. The stem cells divide in the basal crypt 
areas and migrate up to the tip of the crypt thereby differentiating and maturing.   
The enterocytes represent the most abundant cell type of the epithelial lining. 
This absorptive cell type has a columnar shape and possesses microvilli on its 
apical surface to further increase surface area. Its main function is the absorption 
of water, ions, sugars, peptides, lipids and vitamin B12.  
Goblet cells are needed for secretion of mucus and antimicrobial peptides. 
Mucus covers the epithelium and represents the very first line of defense against 
invaders. Its most important component is MUC2, a large protein that is highly 
glycosylated and forms a gel like polymer (together with other glyco-proteins). 
Antimicrobial peptides such as defensins get stuck in the mucin network, which 
leads to high antimicrobial activity at the epithelial surface. Therefore, the mucus 
The human gastrointestinal tract 
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layer is important for regulating the mass and diversity of living bacteria that 
occupy our gut. 
Enteroendocrine cells can release hormones and peptides that can act locally 
or systemically. They also function as chemoreceptors and can detect noxious 
compounds. Hence, this cell type plays a role in regulating digestion and 
connects the gut with the central nervous system. 
Underneath the epithelium the lamina propria is located, a layer of loose 
connective tissue. There is a great number of different cell types within this 
connective tissue, for example: fibroblasts, lymphocytes, plasma cells, 
macrophages, and mast cells. The number and composition of cell types in the 
lamina propria depends on the physiological or pathological state.  However, the 
majority of inhabitant cell types are tissue resident macrophages and IgA 
secreting B-cells. The abundance of immune cells makes the lamina propria a 
key spot for immune defense against invading microbes. 
The muscularis mucosae separates the mucosa from the underlying 
submucosa. It is composed of several thin layers of smooth muscle fibers 
oriented in different ways.  It guarantees the fine tuning of the intestinal surface 
and holds the mucosal glands in a constant state of soft tension to support the 
secretory activity. It is also needed to enhance contact between the epithelium 
and the luminal content. 
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Figure 4-2 Microscopic anatomy of the colon wall (image source: 
adapted from6). The colon wall is built of 3 layers: an external muscle 
layer, the submucosa and the mucosa. The mucosa contains all the 
different cell types that mediate colon and immune function. The luminal 
surface is covered by a mucus layer, secreted by goblet cells. The 
epithelial lining is formed by enterocytes (water absorption), goblet cells 
(mucus secretion) enteroendocrine cells (hormone secretion) and stem 
cells (renewal of the epithelium). 
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4.1.2 The immune system of the colon 
The intestine is the place with the largest contact area between body and 
external environment7. The heavy duty of the intestinal immune system is the 
discrimination between commensals, food and body’s own tissue on the one 
hand and pathogens on the other hand. Disturbances in this homeostasis result 
in inflammation8. The mesenteric lymph nodes are the secondary lymphoid 
structures of the colon. The bean-shaped lymph nodes consist of a cortex with 
separated areas for B- and T-cells and a medulla where a lot of antibodies 
producing plasma cells reside. Antigen presenting cells migrate to the lymph 
nodes to activate lymphocytes.  
There are also isolated lymphoid follicles (ILF), tertiary lymphoid structures, in 
the colon. They develop after birth in response to commensal microbes and 
contain mainly B-cells. During inflammation the lymph nodes and ILF enlarge 
due to hyperproliferating lymphocytes that undergo clonal expansion. There are 
also lymphocytes within the epithelial layer. These cells are important for 
reconstitution after tissue damage 9, 10 and they can stimulate AMP secretion 
from IECs11. The main immune effectors are the immune cells scattered in the 
LP: macrophages, lymphocytes, DCs and mast cells.  
Macrophages are cells of the innate immune system, which help to eliminate 
invading microbes by phagocytosis and can initiate an immune response by 
secreting cytokines. They possess pattern recognition receptors (PRRs) that 
recognize pathogen associated molecular patterns (PAMPs) on microbes such 
as lipopolysaccharide (LPS) or muramyl dipeptide (MDP). Regarding 
lymphocytes, in the lamina propria there are mainly memory T-cells and IgA 
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producing plasma cells. The mucosa is literally drenched in IgA, which is 
important for homeostasis. IgA helps in eliminating pathogens without 
inflammation and is actively translocated to the luminal surface by IECs. Memory 
T cells are easier and faster to activate then naïve T-cells which immediately 
start to secrete effector cytokines such as interferon γ (IFNγ), IL-10 or TGFβ 
after recognizing their specific antigen. Dendritic cells (DCs) sample antigens 
from their environment by macropinocytosis. When activated by pathogens they 
stop macropinocytosis and migrate to the lymph nodes. There, they present the 
sampled antigens to lymphocytes. As all antigen presenting cells (APCs), DCs 
are able to detect pathogens via PRRs. Mast cells are huge and filled with toxic 
granulae which can be quickly released when the cells become activated. 
Intestinal epithelial cells (IECs) also perform immune functions by secreting pro-
inflammatory cytokines to recruit immune cells. Furthermore, IECs express major 
histocompatibility complex II (MHCII) molecules but do not express costimulatory 
signals under physiological conditions12. MHCII is classically expressed by APCs 
to present extracellular antigens to lymphocytes. Without the costimulatory signal 
the lymphocytes become anergic. This way tolerance is induced and immune 
activation is suppressed13. This mechanism is called oral tolerance and is 
important to suppress immune responses against commensals or food antigens. 
Just like APCs IECs also express PRRs, those enable them to recognize 
invading microbes. 
In most cases, the innate immune system is capable to fight the invader. This is 
mainly done by macrophages that sense bacteria and other invaders via PRRs 
followed by phagocytosis. If this doesn’t result in victory over the pathogen, 
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macrophages and mast cells secrete cytokines like tumor necrosis factor (TNF), 
interleukin (IL-) 6 and IL-1 which initiate an inflammation. In the same time DCs 
activate the adaptive immune response by presenting antigens to lymphocytes in 
the mesenteric lymph nodes. The lymphocytes then start clonal expansion and 
several days after infection the cells are ready to fight. An important feature of 
inflammation is the recruitment of neutrophils to the side of infection. They fight 
the invaders by phagocytosis and by secretion of reactive oxygen species 
(ROS). They are chemo attracted to the side of inflammation by IL-8, another 
pro-inflammatory cytokine secreted by macrophages and many other cell types. 
As the most potent macrophage activator, IFNγ has also to be mentioned. 
Activated macrophages are more efficient in phagocytosis. 
4.1.3 Barrier function 
The mucosa separates the body from the environment, thereby forming a barrier 
towards invading microbes. This barrier is made of three components: the mucus 
layer, the epithelial cell layer and the tissue resident macrophages within the 
lamina propria. 
The mucus is made of two layers. Whereas the outer layer is gel like and 
contains few bacteria, the inner layer is more viscous and nearly sterile. 
Antimicrobial peptides secreted by IECs and goblet cells are trapped in the inner 
layer, ready to defeat bacteria that are able to overcome the outer coat. IECs 
also secrete HCO3- and trefoil factor 3. Therefore the mucus is rich in 
bicarbonate to maintain a neutral pH at the epithelial surface. TFF3 crosslinks 
mucins and promotes epithelial repair14. 
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Invaders that are able to pass through the mucus, face the firm layer of epithelial 
cells. To pass this barrier on a paracellular way, bacteria have to squeeze 
through gap between cells. Neighboring IECs are connected to each other via 
desomosomes, adherens junctions and tight junctions. Tight junctions (TJs) form 
the firmest contact, thereby determining the strength of this barrier. Furthermore, 
TJ separate the apical from the basolateral membrane which differ in protein and 
lipid composition and physiological function. This way TJ assist in creating cell 
polarity. TJ form a network of punctuate membranes fusions of neighboring cells, 
so called fibrils. There are transmembrane proteins such as occluding, claudins 
and JAM proteins whose extracellular domains are linked to the ones of 
neighboring cells. These TJ proteins are linked to an aggregation of intracellular 
membrane proteins, zonula occludens proteins, some of which are linked to the 
cytoskeleton.  
TJ are highly regulated structures. There is a direct correlation between fibril 
numbers and barrier integrity. The TJ ”kisses” are impermeable structures with 
channels or pores which can open and close. TJ can be modified by number of 
kisses, channel openings and physical pore changes and can be regulated for 
example by meal related nutrients. TJ disruption contributes to diarrhea by leak 
flux. During transepithelial migration of neutrophils, TJ have to be opened and 
resealed afterwards. Furthermore, TJ are influenced by cytokines. IFNγ leads to 
internalization of TJ proteins thereby reducing barrier function. 
Bacteria that passed the mucus and the IEC layer arrive in the lamina propria 
where they are phagocyted by macrophages. Monocytes circulate in the blood 
and eventually enter the colon or other tissue where they differentiate into tissue 
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resident macrophages. Once matured, they reside in the lamina propria of the 
colon. 
4.2 Inflammatory Bowel Diseases 
Inflammatory bowel diseases (IBD) are a group of chronic and relapsing 
inflammatory conditions of the small and/or large intestine with the two main 
variants Crohn’s disease (CD) and ulcerative colitis (UC). The manifestations of 
IBD depend on the area of intestinal tract involved and the symptoms are not 
specific. Typically, there are symptom free periods between relapses. Patients 
often suffer from diarrhoea with urgencies during night and incontinence with 
mucus or blood containing stool. They further have abdominal pain and 
cramping, nausea and vomiting. These symptoms often lead to weight loss. 
Despite having many things in common, there are some differences between CD 
and UC. CD can affect any part of the gastrointestinal tract but usually the distal 
ileum and colon are involved. It occurs as “skip lesions” between healthy areas 
(cf. Figure 4-3). Cobble stone pattern can typically be observed in colonoscopy 
and the inflammation affects all layers of the gut wall. UC is marked by a 
continuous inflammation starting from the rectum but is restricted to the colon. 
Usually, only the mucosa is inflamed whereas the other layers of the gut wall are 
not affected15. Colonoscopy is the most important test for diagnosing IBD. Even 
small ulcers and mild inflammation can be seen this way and biopsies for 
histological analysis can be taken. 
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Figure 4-3 Distribution of inflammation in ulcerative colitis and 
Crohn's disease (image source:16). In ulcerative colitis the inflammation 
spreads from the rectum and is restricted to the colon, thereby only 
affecting the mucosa (left panel). Crohn’s disease is characterized by 
inflammatory patches that can affect any part of the gastrointestinal tract. 
Furthermore, the inflammation affects the whole intestinal wall.  
When IBD causes severe damage to the colon, it may be needed to be surgically 
removed. This can cure UC but not CD, because in CD the inflammation can 
reoccur in other parts of the gastrointestinal tract. A complication that often 
occurs in CD is the formation of fistulae. Deep ulcers can form abscesses that 
can break through to an adjacent organ creating a fistula. 
People with IBD may have extra intestinal manifestations such as mouth sores 
and skin problems, arthritis, eye problems that affect vision. Furthermore, 
longstanding inflammation is a risk factor for the development of cancer. When 
stressed, lamina propria macrophages release pro-inflammatory signals that 
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may lead to increased probability of developing cancer. An example of this is the 
over activation of the IL6/STAT3 pathway which has been linked to colitis-
associated cancer17. Colorectal cancer (CRC) is the third most frequent cancer 
and the third leading cause of cancer death in the United States18.  
Cytokines play a pivotal role in the development of IBD. The pro-inflammatory 
cytokine TNF is a hallmark in IBD. It is found to be increased in the mucosa of 
IBD patients and correlates with clinical and laboratory indices19. Anti-TNF 
antibody treatment is an established therapy in steroid-refractory CD patients, in 
fistulising CD and also in active UC20. Introduction of anti-TNF therapies in 1998 
had a major impact on IBD management and prognosis21. But the side effects 
are fatal, due to its immune suppressive effects TNF blockers bear the risk for 
severe infections.  
IL-6, another central cytokine in immunity, is found to correlate with clinical and 
histological severity of CD and UC22, 23. After steroid treatment mediated 
remission, elevated IL-6 serum levels are highly predictive for a relapse of the 
disease24, 25. Therefore, IL-6 is an important biomarker in IBD patients. The main 
sources of IL-6 are macrophages and CD4+ T-cells. The majority of 
TNF/IL-1/IL-6 induced pathways are mediated by NFκB and MAPK.  
Another cytokine that also crucial in chronic inflammation is IL-1β, which can be 
detected in the mucosa of IBD patients with active disease and correlates with 
inflammation severity26-28. The main source of IL-1β in colonic mucosa of IBD 
patients are stimulated macrophages.   
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Furthermore, IFNγ should be mentioned as an important cytokine in IBD. As 
noted in chapter 4.1.3, IFNγ stimulation results in barrier defects by disrupting 
TJ29. It also an important activator of macrophages, inhibits IEC migration30 and 
impairs wound healing31, 32. 
4.2.1 The multifactorial pathogenesis of inflammatory bowel diseases 
IBD was seldom seen before the rise of improved hygiene and urbanization at 
the beginning of the 20th century. There is a rising incidence and prevalence 
especially in industrialized nations33. The onset of IBD typically occurs at 15 to 
30 years of age but can occur at any time in life. There is a bimodal age 
distribution with a second smaller peak at the ages of 50 – 70 years34. Until now 
there is no cure to IBD and normally it requires a lifetime of care.  
Although, the multifactorial pathogenesis is still not entirely understood, it is 
generally accepted that IBD results from an uncontrolled inflammatory immune 
response towards otherwise commensal microbiota in genetically predisposed 
individuals. Genetic factors only account for 20-25 % of the heritability found in 
population based studies, leaving much room for environmental factors to 
contribute. This is supported by the fact that IBD is more common in 
Westernized countries than in non-industrialized countries. As individuals move 
from areas of low to high prevalence of IBD, fist-generation offspring acquire the 
same risk as the local population35. Therefore, IBD seems to be a result of the 
“westernized” lifestyle that is marked by changes in diet, smoking behaviour, 
variances in exposure to sunlight, pollution and industrial chemicals36. Hence, 
IBD is a disease of cleanliness, it demonstrates an inverse relationship with the 
degree of sanitation: poor sanitation appears to protect against IBD. Improved 
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hygiene alters the intestinal flora by decreasing exposure to certain critical 
bacteria. Smoking is the strongest environmental risk factor for Crohn’s disease 
but is protective in ulcerative colitis:  current smoking protects against UC (40% 
reduced risk to develop UC), whereas ex-smoker show higher risk to develop UC 
(1,7 times increased) than those who never smoked37. 
A topic that recently aroused much interest and that may link genetic and 
environmental factors is the role of the microbiota38. The microbiota of our gut is 
influenced by nearly everything in our environment, by everything we eat or 
drink. The microbiota itself can profoundly alter our immune composition and IBD 
patients show different microbiota compared to healthy individuals38. Also, in the 
mouse models of IBD the microbiota is crucial for disease development. Mice 
kept under germ free conditions don´t show inflammation in the model of 
chemical or genetically induced colitis. 
4.2.2 Risk Genes 
Epidemiological and family studies demonstrated the involvement of genetic 
factors, but nevertheless IBD cannot be explained by a single gene model 
alone39.  It is not surprising that UC and CD share some but not all susceptibility 
loci. The disease phenotype is determined by several factors including 
interaction between allelic variants at a number of loci as well as genetic and 
environmental influences39. The presence of one mutated gene is not sufficient 
to predict IBD40. 
Approximately 30% of IBD-related genetic loci are shared by UC and CD, 
indicating common pathways41. These are normally pathways that are crucial for  
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intestinal homeostasis such as barrier function, epithelial restitution, microbial 
defence, innate immune regulation, ROS generation, autophagy, regulation of 
adaptive immunity, endoplasmic reticulum (ER) stress and metabolic pathways 
associated with cellular homeostasis41. More than 50% of IBD susceptibility loci 
have also been associated with other inflammatory and autoimmune diseases41. 
The strongest association with IBD was found for a single nucleotide 
polymorphism (SNP) within gene encoding the nucleotide-binding 
oligomerisation domain 2 (NOD2), an intracellular pattern recognition receptor 
that is activated by MDP, a peptidoglycan common to all bacteria. If NOD2, 
expressed by leukocytes and IECs, is not properly functioning, more bacteria are 
able to invade the tissue and can provoke inflammatory immune response. 
X-box binding protein 1 (XBP1) is an example for a susceptibility gene of the ER 
stress pathway. This transcription factor is activated via the ER stress sensor 
inositol-requiring enzyme 1 (IRE1) by differential splicing (cf. chapter 0). 
Dysfunctional XBP1 in IECs leads to unresolved ER stress, which renders the 
cells more prone to inflammation42. 
This thesis is focussed on the IBD risk gene encoding protein tyrosine 
phosphatase non-receptor type 2 (PTPN2) that was also found to be associated 
with diabetes type 1 and rheumatoid arthritis.  
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4.3 Protein Tyrosine Phosphatase Non-Receptor Type 2 
The protein tyrosine phosphatase non-receptor type 2 (PTPN2) is a phosphatase 
that removes phosphate groups from proteins at their tyrosine residues. 
Phosphatases are important enzymes in signal transduction. If the cell receives 
a signal from the environment due to ligand binding at a surface receptor, this 
leads to changes in conformation of the intracellular part of the receptor. This 
changed conformation enables the receptor protein to act as a kinase and to 
phosphorylate a target protein, thereby activating it. To end the signal, 
phosphatases are needed to remove the phosphate groups to set the enzymes 
back into an inactive state. 
The phosphatase PTPN2 is ubiquitously expressed in all embryonic and adult 
mammalian tissues, but can be found in particular high amounts in cells of 
hematopoietic origin43. The PTPN2 gene is located on chromosome 18 in 
humans and in mice within a syntenic region44. In humans there are two common 
isoforms generated by alternative splicing: the 45 kDa variant is located in the 
nucleus whereas the 48 kDa form is found in the cytoplasm bound to the ER45. 
The 48 kDa isoform was first cloned from a human T-cell cDNA library43 and 
therefore PTPN2 is sometimes also called T cell protein tyrosine phosphatase 
(TCPTP). For catalytic activity the nuclear variant seems to be more important. 
Upon activation it can exit the nucleus and attain to the cytoplasm where it can 
dephosphorylate target proteins. It has many known targets, the most important 
ones are: epidermal growth factor receptor (EGFR), insulin receptor and the 
signal transduction and activators of transcription molecules STAT1, 3 and 5. 
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The PTPN2 knockout mouse was the first mouse carrying the knockout of a 
protein tyrosine phosphatase generated nearly 20 years ago46. The recent 
development of conditional knockout mouse models47-49 helped to identify a 
great number of phenotypes related to PTPN2 depletion. PTPN2 has been found 
to act on a broad list of physiological events such as inflammatory response50, 
hematopoietic stem cells renewal51, insulin signaling52 and leptin regulation53. 
4.3.1 PTPN2 in IBD 
Besides the correlations that were found in genome wide association studies 
(GWAS), there are some experimental findings that connect PTPN2 to IBD. First, 
PTPN2 protein expression is increased in colon tissue specimens of patients that 
suffer from active CD54, 55. This finding is strengthened by experiments on IEC 
cell lines that show an elevated PTPN2 expression after stimulation with the IBD 
associated pro-inflammatory cytokines IFNγ and TNF54, 55. Furthermore, PTPN2 
deficiency induced by siRNA in IECs leads to an aggravated increase in IFNγ 
induced barrier defects54. Those barrier defects manifests in increased 
transepithelial resistance (TER), increased Claudin2 (a pore forming TJ protein) 
expression and increased permeability to FITC-dextran54. TNF stimulation of 
PTPN2 deficient IECs leads to exaggerated increase in secretion of the pro-
inflammatory cytokines IL-6 and IL-8. 
Epidermal growth factor (EGF) stimulation of IECs that are transfected with 
PTPN2 siRNA show increased EGFR phosphorylation56. This points to the fact 
that PTPN2 boosts EGF induced suppression of Ca2+ dependent Cl- 
secretion56. Carrying a PTPN2 mutation could therefore contribute to diarrhoea 
in IBD patients. 
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PTPN2 is also involved in the regulation of autophagy, a cellular process 
responsible for degradation of cellular components. In vitro studies demonstrate 
that IECs with knocked down PTPN2 expression are not capable of functional 
autophagy57. Upon infection with Listeria monocytogenas, this impaired 
autophagy results in ineffective clearance of bacteria57. Primary colonic lamina 
propria fibroblasts isolated from CD patients that carry the IBD associated 
PTPN2 variant behave the same way57. Furthermore, biopsies from active 
inflamed regions feature aberrant LC3BII expression patterns, indicative for 
dysfunctional autophagy57.  
Taken together this shows the importance of PTPN2 for maintaining the 
intestinal barrier.  
 
Figure 4-4 Signaling pathways regulated by PTPN2 (image source: 
adapted from58). PTPN2 deficiency leads to increased cytokine secretion 
by dephosphorylation of STAT and MAPK molecules. In addition, PTPN2 
is essential for autophagy. Lack of PTPN2 in T cells results in 
exaggerated activation of TCR-associated kinases resulting in loss of 
tolerance towards self-antigen. 
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In THP-1 cells PTPN2 expression is elevated by IFNγ stimulation accompanied 
by decreased phosphorylation of STAT1 and STAT359. In PTPN2 deficient 
circumstances IFNγ treatment causes increased levels of phosphorylated STAT1 
and STAT3 and MAPK activity as well as increased secretion of the macrophage 
attractant cytokines IL-6 and MCP159. The importance of PTPN2 in monocytes is 
also emphasized by other experiments. PTPN2 knockout mice die from systemic 
inflammation and exhibit high serum levels of IFNγ and intense tissue infiltration 
by monocytes50. Isolated macrophages of these animals are hypersensitive to 
LPS50. 
PTPN2 was discovered by screening a human T cell cDNA library and it is 
known to be expressed at high levels in T cells. Therefore it is not surprising that 
PTPN2 plays a major role in this cell type. Mice with a T cell specific PTPN2 
knockout display strong inflammation and autoimmunity which can be passed on 
wild type mice by transfer of CD8+ cell59. The mice with T cell specific knockout 
possess TCRs with lowered threshold for CD8+ proliferation49. In PTPN2 
competent naive T cells, PTPN2 expression restricts homeostatic proliferation60. 
When CD8+ cells with PTPN2 deficiency are transferred into wild type recipients 
the T cells acquire features of antigen experienced cells60. The elevated TCR 
response contributes to a distorted TCR repertoire that results in autoimmunity60. 
Furthermore, when OVA specific T cells are transfected into mice that express 
OVA in β-cells this causes islet destruction in the pancreas only when co-
transfected with OVA specific CD4+ cells61. If PTPN2 deficient OVA specific 
CD8+ cells are transfected, this also gives rise to β-cell destruction and 
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diabetes61. This reveals that PTPN2 is involved in mediating peripheral T cell 
tolerance. 
The PTPN2 knockout mouse clarifies the relevance of this phosphatase for 
haematopoiesis and immune function. Mice heterozygous for PTPN2 have bone 
marrow defects and impaired B and T cell function but the development of 
myeloid cells and macrophages is normal46. Bone marrow transfer from wild type 
donors to heterozygous PTPN2 mice does not rescue the phenotype, thereby 
illustrating possibility that hematopoietic defects are probably caused by stromal 
abnormalities46. Another study could show that PTPN2 deficient stromal cells are 
capable to secrete high amounts of IFNγ which prevents B cell maturing and 
leads to enhanced B cell apoptosis62. 
All this data emphasize the central role of PTPN2 in many different cell types 
and also the diversity of cellular processes that depend on this phosphatase. 
4.4 Endoplasmic reticulum stress 
In addition to the above mentioned processes that connect PTPN2 to IBD, a part 
of this work centres on the possibility that PTPN2 might contribute to IBD 
pathogenesis by interfering with ER stress signalling. The connection between 
PTPN2 and ER stress is already made by a study showing that knockdown of 
PTPN2 leads to increased ER stress followed by apoptosis in pancreatic 
β-cells63.  Due to high secretory activity IECs are as prone to ER stress as 
β-cells. If there is a PTPN2 deficiency or malfunction this could result in 
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exaggerated ER stress in IECs, which then could lead to inflammation favouring 
IBD.  
The ER plays a central role in the secretory pathway. Proteins that are destined 
to be secreted are synthesized by ribosomes attached to the ER membrane. 
Inside the ER, chaperones assist in correct folding and enzymes add post-
translational modifications. Then correctly folded proteins are translocated to the 
Golgi where they are packed into vesicles and carried to the plasma membrane. 
The secretion is conducted by fusion of the vesicle with the plasma membrane, 
thereby expelling the vesicle content in the cell surroundings. 
Misfolded proteins are delivered to the cytoplasm and marked for degradation in 
the proteasome. This mechanism is called ER-associated degradation (ERAD). 
ER stress occurs when disturbances of the ER homeostasis lead to an 
accumulation of misfolded proteins. There are three different transmembrane 
proteins located in the ER membrane, which are able to sense an abnormal 
increase in misfolded proteins: IRE1, protein kinase RNA-like endoplasmic 
reticulum kinase (PERK) and activating transcription factor (ATF6) (cf. Figure 
4-5). Each of these stress sensors then initiates a different signalling cascade. 
Together these three pathways are called unfolded protein response (UPR) and 
aim to resolve ER stress by degradation of misfolded proteins and stopping 
global protein synthesis but permitting chaperon expression. 
During ER homeostasis, the chaperon binding immunoglobulin protein (BiP) is 
bound to the luminal domain those three transmembrane proteins. When more 
chaperons are needed to assist in protein folding, BiP is released thereby 
activating stress sensors. This leads to oligomerisation and autophosphorylation  
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Figure 4-5 The 3 pathways that activate unfolded protein response 
(UPR)  (image source:64).There are 3 transmembrane proteins that are 
able to sense ER stress and each initiates a different signaling cascade: 
PERK, IRE1α and ATF6. Activated PERK phosphorylates eIF2α and Nrf2. 
Activated eIF2α increases translation of ATF4 mRNA and ATF4 protein 
operates as transcription factor, thereby inducing genes involved in amino 
acid metabolism, autophagy, antioxidant responses and apoptosis. If 
IRE1α becomes activated by accumulation of unfolded proteins, it 
controls selective mRNA decay and splicing of XBP1 mRNA. The spliced 
mRNA can then be translated into XBP1 protein, a transcription factor 
responsible for upregulation of UPR genes involved in folding, organelle 
biogenesis, ERAD autophagy and protein quality control. Third ER stress 
sensor ATG6 is transported to the Golgi upon ER stress induction where 
a cleavage results in release of the cytosolic domain. This cytosolic ATF6 
domain then enters the nucleus and mediates expression of ER 
chaperons, ERAD-related genes and proteins involved in ER/Golgi 
expansion.  
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of the cytosolic IRE1α and PERK domain. IRE1α thereby activates its RNase 
domain to process X-box binding protein 1 (XBP1) mRNA which then can be 
translated into protein. XBP1 is a transcription factor that initiates UPR 
 associated genes. Activated PERK has kinase function and phosphorylates 
eukaryotic initiation factor 2 (eIF2α). EIF2α is necessary for general initiation of 
translation and is set to inactive state by phosphorylation. This way global 
protein synthesis is stopped. However, activated ATF6 translocates to the Golgi 
where it is cleaved. The ATF6 p50 fragment of the cytosolic domain then enters 
the nucleus and promotes expression of chaperones. If ER stress cannot 
resolved by these mechanisms the cell undergoes apoptosis.  
ER stress is already known to play a role in immunity and inflammation. IRE1α 
can also be activated via toll-like receptor (TLR) signalling and consequentially, 
XBP1 can support the expression of pro-inflammatory cytokines in 
macrophages65. In contrast, TLR signalling in macrophages can also prevent 
ATF6 activation66. Furthermore, dysfunctional UPR has been associated with 
IBD and other autoimmune diseases such as multiple sclerosis and rheumatoid 
arthritis67. As already mentioned, XBP1 is one of the IBD risk genes that plays a 
role in the ER stress signalling. This goes in line with the finding that tissue 
specific XBP1 knockout in IECs results in spontaneous enteritis68. This 
inflammation is mediated by Paneth cell dysfunction and IEC’s hyper reactivity 
towards TNF and flagellin. UPR plays a role in tumorigenesis, too. The growth 
conditions within a tumor typically feature ER stress triggers like hypoxia, low pH 
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and starvation. Indeed, inhibition of XBP1 protein leads to increased apoptosis, 
suggesting its importance for tumor survival69. 
As described above, UPR mechanisms play a central role in IBD pathogenesis 
and it is already shown that PTPN2 interacts with ER stress signalling in β-
cells63. Thus, it sounds reasonable that PTPN2 mediated susceptibility to IBD is 
caused by dysfunctional PTPN2 in IEC causing exaggerated ER stress 
ultimately favouring IBD.  
4.5 Models for IBD research 
To investigate pathological mechanisms of IBD many in vitro and in vivo models 
are available.  
4.5.1 In vitro models for IBD 
The intestinal mucosa contains a large number of different cell types that can 
affect the epithelium. In vitro models allow the isolated examination of a single 
cell type without complex interaction with surrounding cells and tissues. It 
permits the complete control over the experimental conditions: cell type, 
growth/culture conditions and addition of stimulatory molecules are well defined 
and the over-/under-expression of a protein of interest is easy to facilitate. In 
vitro studies can target potential key cells or mediators in any 
physiological/pathological process. Additionally, the expression of a particular 
molecule in the cell type of interest is possible. An array of IEC cell lines derived 
from colon carcinoma are available. Seeded on filter supports they form a 
polarized monolayer thereby allowing the investigation of effects of different 
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stimuli on barrier function and vectorial ion transport. Co-culture of IECs with 
other cells such as immune cells adds more complexity to the system. It can be 
used for example to define the cellular interactions that regulate the epithelium. 
Adding neutrophils to the basolateral compartment can be useful to study 
transepithelial migration, when a chemoattractant (such as N-formylated peptide) 
is added apically. It is also possible to study early events and cellular response 
to a given microbe. However, data obtained from experiments with cell lines 
have to be interpreted carefully. It needs to be kept in mind that cell lines are 
immortalized and derive from cancerous tissues, therefore they may not exactly 
mimic the behaviour of IECs in vivo. Immortalization and transformation often 
alter IEC’s specific response to drugs and treatments. Nevertheless, in vitro 
studies are suitable instruments to investigate effect on barrier function, ion 
transport, absorption mechanisms, injury and repair mechanisms and immune 
events. 
4.5.2 In vivo models to study IBD 
For in vivo studies several mouse models are available. Many transgenic mouse 
strains exist for example tissue specific knockout and inducible promotors. Some 
transgenic mouse strains spontaneously develop colitis. The most common one 
is the IL-10 knockout mouse. The cytokine IL-10 plays a key role in suppression 
of the immune system by mediating inhibition of T cell activation. It directly acts 
on APCs and leads to down regulation of MHCII and co-stimulatory molecules 
and inhibition of IL-12 secretion70. IL-10 knockout mice develop colitis by 2-4 
month of age with a transmural inflammation and they often develop 
osteoporosis (as do CD patients) and colon cancer71. There are also some other 
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mouse strains that develop spontaneous colitis such as IL-2 knockout, MHCII 
knockout or TGFβ knockout mice72. A major issue with these models is that 
onset and severity of colitis are variable and also depend on cleanliness of the 
animal facility. Germ free mice with IL-10 deficiency do not develop colitis. 
Obviously, a trigger from microbiota is necessary for the development of 
spontaneous colitis. Another difficulty with all these models (and with mice 
experiments in general) is the great importance of the genetic background. For 
example C57BL/6J IL-10 knockout mice develop only mild colitis whereas a C3H 
background leads to more severe colitis73. 
Infection models allow pathogen host interaction studies. Citrobacter rodentium 
and Salmonella typhimurium are often used in mice that are pre-treated with 
antibiotics to remove the normal gut microbiota prior infection. However, 
pathogenesis of murine infections often differs from human: Salmonella infection 
leads to gastroenteritis in humans but mice get a systemic disease. Early 
interaction events are specific for every microbe but the late consequences are 
remarkably uniform: release of chemoattractant cytokines, NF-κB mediated 
response, IEC apoptosis and altered cell function due to bacterial products. 
There are also some chemical inducible models for IBD available. The most 
common one is the dextran sodium sulphate (DSS) induced colitis. DSS is 
directly toxic to IECs thereby leading to colon inflammation that resembles UC. 
This inflammation is accompanied by hyperemia, ulcerations, submucosal 
edema, lesions, infiltration of granulocytes, bloody diarrhoea and weight loss. 
DSS can be mixed into the drinking water for 7 days to induce acute colitis. 
Development of chronic colitis is also possible by administering 4-5 cycles of 
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DSS dispersed by water treatment. Severity and onset of colitis can be 
controlled via concentration and duration of DSS treatment. But again, the 
genetic background and cleanliness greatly influence colitis severity. There are a 
lot of other chemicals available that are also suitable to induce colitis. The most 
important ones are trinitrobenzenesulfonic acid (diffuse colonic transmural 
inflammation) and oxazolone (model for UC). Both chemicals have to be 
dissolved in ethanol and are applied intrarectally. Furthermore, the DSS colitis 
can be combined with i.p. injection of azoxymethane (AOM) to induce the 
development of CRC. 
Another possibility to study IBD pathogenesis is the adoptive transfer. Naïve 
CD4+ T cells from healthy wild type mice are injected into syngenic 
immunedeficient recipients (RAG knockout or SCID mice) who develop colitis 
after 5-8 weeks. Transfer colitis mimics the histological features of human UC 
with crypt abscesses, ulcerations and infiltration in the mucosa. It is a useful 
method to study the very earliest immunological events, perpetuation of the 
disease and the role of regulatory T cells. The adaptive transfer experiments are 
easy to perform, highly reproducible and show many similarities to human IBD. 
Also bone marrow reconstitution is possible 
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Figure 4-6  Model of DSS colitis and AOM/DSS induced development 
of colorectal cancer (image source: adapted from 74). 
4.5.3 Mixed models to study IBD  
In vivo studies are cost intensive and only limited data end points are possible 
because mice have to be killed to remove the colon for detailed analysis. Long 
term culture of isolated intestinal crypts or intestinal stem cells75 combines the 
advantages from both in vitro and in vivo studies. Supplemented with growth 
factors and three dimensional extracellular matrix these stem cells develop into 
organoids and enteroids. This is useful to study intestinal stem cell self-renewal, 
growth and differentiation. In vitro expanded organoids may be used for stem cell 
therapy in preclinical animal models76 or to study toxicity and cell death 
induction. Furthermore, organoids from transgenic mice can be used to study the 
impact of certain proteins. 
Xenocraft models allow the performance of experiments with human tissue by 
transplanting biopsies of human intestine s.c. into immunodeficient mice (SCID 
or Rag-/-). After initial degradation the graft begins to regrow small segments 
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after 10 weeks. Additionally, the graft can be injected with microbes or their 
products. But this method has its limits: for example adoptive cell transfer is not 
possible because human myeloid cells cannot invade graft when vascularisation 
is of mouse origin. 
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5 OBJECTIVES 
5.1 Aim of the project and addressed topics 
GWAS found PTPN2 to be associated with IBD (also to diabetes type 1 and 
rheumatoid arthritis). When starting the project, it was already known that 
PTPN2 interferes with ER stress signalling in pancreatic β-cells and that PTPN2 
deficiency in IECs leads to barrier defects and impaired autophagy. Therefore, it 
was a promising approach study the role of PTPN2 in ER stress signalling in 
IECs and monocytes, two cell types that are heavily involved in IBD 
pathogenesis. There are some other known ER stress modulators among the 
IBD susceptibility genes, so this could reveal the mechanism by which PTPN2 
mediates predisposition to IBD. 
Already available in vivo data showed that total loss of PTPN2 is lethal. Mice 
with a global PTPN2 knockout die few weeks after birth on systemic 
inflammation. To look at the role of PTPN2 specifically in IECs we generated 
mice with a tissue specific knockout. We expected these PTPN2xVilCre mice to 
be more susceptible to DSS induced colitis. 
Within this project, following topics were addressed: 
- in vitro: impact of PTPN2 knockdown on ER stress in THP-1 and HT-29 
cells
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- in vivo: effect of tissue specific PTPN2 knockout in IECs on DSS induced 
colitis 
5.2 Contribution to further projects during the time of the 
dissertation (not addressed in detail within this work) 
5.2.1 PTPN2 controls differentiation of CD4+ T cells and limits 
intestinal inflammation and intestinal dysbiosis 
Loss of PTPN2 in the T cell compartment causes enhanced induction of Th1 and 
Th17 cells, but impaired induction of regulatory T cells in several mouse colitis 
models, namely acute and chronic dextran sodium sulfate colitis, and T cell 
transfer colitis models. This results in increased susceptibility to intestinal 
inflammation and intestinal dysbiosis which is comparable with that observed in 
CD patients. We detected inflammatory infiltrates in liver, kidney, and skin and 
elevated autoantibody levels indicating systemic loss of tolerance in PTPN2 
deficient animals. CD patients featuring a loss-of-function PTPN2 variant exhibit 
enhanced Th1 and Th17 cell, but reduced regulatory T cell markers when 
compared with PTPN2 wild type patients in serum and intestinal tissue samples. 
Our findings indicate a novel and crucial role for PTPN2 in chronic intestinal 
inflammation. 
Spalinger MR*, Kasper S, Raselli T, Frey-Wagner I, Gottier C, Lang S, Atrott K, 
Vavricka SR, Mair F, Becher B, Lacroix C, Fried M, Rogler G, Scharl M 
Mucosal Immunology 2014, [Epub ahead of print] 
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doi:10.1038/mi.2014.122. 
5.2.2 Activation of protein tyrosine phosphatase non-receptor type 2 by 
spermidine exerts anti-inflammatory effects in human THP-1 
monocytes and in a mouse model of acute colitis 
Activation of PTPN2 by spermidine ameliorates IFNγ induced inflammatory 
responses in THP-1 cells. Furthermore, spermidine treatment significantly 
reduces disease severity in mice with DSS-induced colitis; hence, spermidine 
supplementation and subsequent PTPN2 activation may be helpful in the 
treatment of chronic intestinal inflammation such as IBD. 
Moron B*, Spalinger M*, Kasper S, Atrott K, Frey-Wagner I, Fried M, McCole 
DF, Rogler G, Scharl M 
PLoS One. 2013; 8(9): e73703. 
doi:10.1371/journal.pone.0073703 
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knockdown of PTPN2 made THP-1 cells more susceptible to 
ER stress, PTPN2 deficiency reduced ER stress responses in 
HT-29 IECs. This suggests that PTPN2 regulates adaptation to 
ER stress in a cell type-specific manner.  © 2015 S. Karger AG, Basel 
 Introduction 
 Inflammatory bowel diseases (IBD), a group of chron-
ic inflammatory conditions of the colon and the small 
intestine, are rampant in industrialized nations  [1] . The 
main types of IBD are Crohn’s disease (CD) and ulcer-
ative colitis (UC)  [2] . Both genetic and environmental 
factors contribute to the pathogenesis of IBD. The current 
hypothesis suggests that a defect in the intestinal epithe-
lial barrier results in an over-activation of the immune 
system in response to the commensal flora that ultimate-
ly leads to chronic intestinal inflammation  [3] . Several 
genome-wide association studies revealed numerous 
gene loci that mediate susceptibility to IBD  [4] . Among 
them is the locus encoding the protein tyrosine phospha-
tase non-receptor type 2 (PTPN2) (also called T cell pro-
tein tyrosine phosphatase (TCPTP))  [5, 6] , which was 
also found to be associated with other chronic inflamma-
tory and autoimmune diseases such as type 1 diabetes 
(T1D) and rheumatoid arthritis (RA)  [7, 8] .
 Key Words 
 Inflammatory bowel disease · PTPN2 · ER stress 
 Abstract 
 Background/Aims: Genetic polymorphisms within the gene 
locus encoding protein tyrosine phosphatase non-receptor 
type 2 (PTPN2) have been associated with inflammatory 
bowel disease (IBD). A recent study demonstrated that 
PTPN2 regulates ER stress signalling in pancreatic β-cells. 
Therefore, we investigated whether PTPN2 regulates ER 
stress pathways, apoptosis and cytokine secretion in human 
intestinal epithelial cells (IECs) and monocytes.  Methods: 
THP-1 and HT-29 IECs were stimulated with 2 μg/ml tunica-
mycin (TNM) for the indicated periods of time. For knock-
down experiments, cells were transfected using a mixture of 
three different PTPN2-specific siRNA oligonucleotides. Cell 
lysates were analysed by Western blot and real-time PCR. 
 Cytokine secretion was studied by ELISA measurements of 
cell culture supernatant.  Results: TNM treatment reduced 
PTPN2  protein levels in HT-29 IECs and THP-1 monocytes. 
Knockdown of PTPN2 in THP-1 monocytes led to an exagger-
ated induction of phospho-eIF2α, enhanced PARP cleavage, 
indicative of apoptosis, and attenuated IL-8 and TNF secre-
tion upon TNM stimulation. In HT-29 cells PTPN2 deficiency 
caused reduced phosphorylation of eIF2α and PARP cleav-
age under ER stress conditions.  Conclusions: Whereas the 
 Published online: March 25, 2015 
 PD Dr. med. Michael Scharl 
 Division of Gastroenterology and Hepatology
University Hospital Zurich ,  Rämistrasse 100 
 CH–8091 Zurich (Switzerland) 
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 Some IBD susceptibility loci are also associated with 
endoplasmic reticulum (ER) stress  [4] . ER stress-induced 
inflammation plays a central role in the pathogenesis of 
many metabolic, airway and intestinal diseases  [9] : it is an 
important factor in the development of cystic fibrosis (CF) 
and provides the link between obesity and type 2 diabetes 
(T2D)  [9] . ER stress arises when unfolded or misfolded 
proteins accumulate in the ER, thus initiating the unfold-
ed protein response (UPR) and limiting further transla-
tional events. The accumulation of un- and misfolded 
proteins can be sensed by three different transmembrane 
proteins located in the ER membrane that collaborate to 
minimize the cellular protein load. These sensor proteins, 
namely protein kinase RNA-like endoplasmic reticulum 
kinase (PERK), inositol-requiring enzyme 1 (IRE1) and 
activating transcription factor 6 (ATF6), subsequently ini-
tiate specific signalling cascades that ultimately result in 
the activation of the UPR  [10] . If ER stress persists, the 
UPR triggers apoptosis and local inflammation  [11] . De-
regulated ER stress responses have been shown to play a 
critical role in the onset of intestinal inflammation  [12] .
 During CD in particular, an increased rate of intestinal 
epithelial cell (IECs) apoptosis can be observed and criti-
cally contributes to an increased passage of ions and water 
as well as of bacterial and food antigens across the intes-
tinal epithelium  [13–15] . These apoptosis-related barrier 
defects can be induced by tumor necrosis factor (TNF) in 
vitro  [16] , while the extent of TNF-induced apoptosis is 
potentiated by co-administration of interferon gamma 
(IFN-γ)  [17] . In contrast, a decreased number of apop-
totic events in inflammatory cells, such as lymphocytes or 
monocytes, located in the intestinal lamina propria has 
been observed in IBD, thus contributing to an over-
whelming inflammatory state  [18, 19] .
 In a recent study, PTPN2 was shown to be critically 
involved in ER stress signalling in pancreatic β-cells  [20] , 
whereby the induction of ER stress resulted in a decline 
in PTPN2 expression. On the other hand, knockdown 
of  PTPN2-alleviated tunicamycin (TNM)-induced ER 
stress and protected the cells from ER stress-induced 
apoptosis. Furthermore, the study showed that PTPN2 
mainly regulates the PERK/eukaryotic initiation factor 
2α (eIF2α) branch of the ER stress signalling pathways 
 [20] . We have previously shown that PTPN2 expression 
is altered during acute inflammation in CD and UC  [21] 
and further that PTPN2 regulates cytokine secretion and 
apoptosis in human IECs and monocytes  [22, 23] .
 Therefore, the aim of our study was to investigate 
whether PTPN2 might be a key regulator of ER stress in 
human monocytes and intestinal epithelial cells. We 
demonstrate through this study that PTPN2 controls the 
PERK/eIF2α pathway of the UPR resulting in altered lev-
els of apoptosis and secretion of pro-inflammatory cyto-
kines. Worthy of note is that these effects were clearly 
dependent on a specific cell type.
 Materials and Methods 
 Cell Culture and Stimulation Protocols 
 Human monocytic THP-1 cells (Sigma-Aldrich, St. Louis, Mo., 
USA) were cultured in RPMI 1640 medium (Life Technologies, 
Gibco, Carlsbad, Calif., USA) with additional 10% fetal calf serum 
(FCS) and were maintained in a 5% CO 2 and 95% humidified in-
cubator at 37  °  C. Cells were seeded 5 h prior to experiment in 1 ml 
of FCS-free RPMI 1640 medium at 1 × 10 6 cells/ml per well. Hu-
man intestinal epithelial cells HT-29 (ACC 299, DSMZ, Braunsch-
weig, Germany) were cultured in DMEM medium (Life Technolo-
gies, Carlsbad, Calif., USA) with additional non-essential amino 
acids solution (Life Technologies, Gibco) and 10% FCS and were 
maintained at 37   °   C in an incubator with 10% CO 2 and 95% hu-
midity. Cells were seeded for 24 h and transferred into FCS-free 
medium 5 h prior to experiments. TNM (obtained from Sigma 
Aldrich and dissolved in DMSO) was administered in a concentra-
tion of 2 μg/ml for the indicated periods of time.
 Preparation of Whole Cell Lysates 
 Cells were washed twice with phosphate buffered saline (PBS) 
and lysed in M-Per Mammalian protein extraction reagent (Pierce 
Biotechnology, Rockford, Ill., USA) supplemented with protease 
inhibitors (Roche, Basel, Switzerland) for 30 min on ice. After cen-
trifugation (10 min at 13,000  g ), cell lysate supernatants were as-
sayed for protein content using a NanoDrop spectrophotometer 
(NanoDrop ND1000; Pierce Biotechnology).
 Western Blotting 
 Each lysate was mixed with NuPAGE ® 4× LDS Sample Buffer 
(Life Technologies) loading buffer, 500 m M dithiothreitol (DTT) 
and boiled for 5 min at 95   °   C. Proteins were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred 
onto nitrocellulose membranes (Millipore, Billerica, Mass., USA). 
Membranes were blocked during 1 h with blocking solution (3% 
milk powder (C. Roth GmbH + Co. KG, Karlsruhe, Germany) and 
1% bovine serum albumin (BSA) (GE Healthcare, PAA Laborato-
ries GmbH, Pasching, Austria)) in aqua bidest. Primary antibodies 
[monoclonal mouse anti-human PTPN2 antibody was obtained 
from Merck Millipore; monoclonal rat anti-chicken gp96 antibody 
from Enzo Life Sciences; polyclonal rabbit anti-human eIF2α, 
monoclonal rabbit anti-human phospho-eIF2α (Ser 51 ) and poly-
clonal rabbit anti-PARP were obtained from Cell Signaling Tech-
nologies (Danvers, Mass., USA)] were diluted in blocking solution 
(1: 1,000 for all experiments). For phospho-eIF2α detection we 
used 3% BSA in bi-distilled water for blocking and antibody incu-
bation. Membranes were incubated in primary antibody solution 
overnight at 4  °  C and then washed with washing buffer (Tris buff-
ered saline containing 1% Tween 20) for 30 min. Horseradish per-
oxidase (HRP)-labelled secondary anti-mouse- or anti-rabbit-
IgG-antibody (1: 5,000; Santa Cruz Biotechnologies, Santa Cruz, 
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Calif., USA) in blocking solution was added for 1 h and mem-
branes were washed again for 30 min. Immunoreactive proteins 
were detected using an enhanced chemiluminescence detection kit 
(Thermo Scientific, Rockford, Ill., USA).
 RNA Isolation and Complementary DNA Synthesis 
 THP-1 cells were washed with ice-cold phosphate buffered 
 saline (PBS) and disrupted in RLT buffer (Qiagen, Venlo, the 
 Netherlands) and 1  M DTT solution. Total RNA was isolated using 
RNeasy Plus Mini Kit (Qiagen) according to the manufacturer’s 
instructions. RNA concentration was measured by absorbance at 
260 and 280 nm (NanoDrop ND1000). Complementary DNA 
(cDNA) synthesis was performed using a High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems, Foster City, Calif., 
USA) following the manufacturer’s instructions.
 Real-Time Polymerase Chain Reaction 
 Real-time polymerase chain reaction (PCR) was performed us-
ing FAST qPCR MasterMix for Taqman Assays (Applied Biosys-
tems) on a Fast 7900HT Real-Time PCR system using SDS Soft-
ware (Applied Biosystems). Measurements were performed in 
triplicates, human β-actin was used as an endogenous control, and 
results were analysed by the ΔΔCT method. The real-time PCR 
was comprised of 45 cycles consisting of a denaturing (95  °  C, 20 s) 
and an annealing/extending (60  °  C, 20 s) step. Gene expression as-
says were all obtained from Applied Biosystems.
 Small Interfering RNA (siRNA) Transfection 
 Three different annealed silencer predesigned siRNA oligonu-
cleotides targeting the ptpn2 gene were obtained from Life Tech-
nologies Ltd. Per transfection, 100 pmol of each of the three gene-
specific siRNA oligonucleotides were transfected into 1 × 10 6 
 THP-1 or HT-29 cells using the Amaxa nucleofector system (Lon-
za, Walkersville, Md., USA) or 100 pmol of Silencer Negative 
 Control No. 1 siRNA (life technologies) according to the manufac-
turer’s instructions resulting in a final siRNA concentration of 
1 nmol/ml. After transfection, cells were cultured in 1 ml medium 
for 36 h  before treatment.
 Enzyme-Linked Immunosorbent Assay (ELISA) 
 Supernatant of THP-1 and HT-29 cells were collected and 
stored at –20  °  C. ELISA kits detecting human IL-8 and human TNF 
were obtained from Qiagen. Assays were carried out according to 
manufacturer’s recommendations and absorbance was detected at 
450 nm on a BioTek-Synergy Luminescence Reader using Gen 
5.1.1.1 Software. Measurements were performed in duplicates.
 Annexin V Staining 
 Cells were collected, washed in PBS, transferred into 190 μl 
FACS binding buffer (10 m M HEPES/NaOH pH 7.4, 140 m M 
NaCl, 2.5 m M CaCl 2 ), 5 μl annexin V-APC antibody (Enzo Life 
Science) and 5 μl propidium iodide (Fluka) were added. After 10 
min incubation at room temperature in the dark, cells were washed 
in PBS and resuspended in 200 μl FACS binding buffer. Analysis 
of apoptosis was done using FACS-Canto II flow cytometry.
 Statistical Analysis 
 Statistical analysis was performed using ANOVA and Student 
Newman Kels post-hoc test using GraphPad Software (Instat, San 
Diego, Calif., USA).
 Results 
 ER Stress Reduces PTPN2 Protein Levels in THP-1 
Cells 
 To study the possible involvement of PTPN2 in ER 
stress signalling in human THP-1 monocytes, we treated 
THP-1 cells with TNM to induce ER stress. The cells were 
stimulated with 2 μg/μl TNM for 2 and 18 h and lysates 
were analysed by Western blot for PTPN2 expression 
and for ER stress-associated proteins. As expected, TNM 
stimulation led to enhanced eIF2α phosphorylation ( fig. 
1 a) and increased protein levels of the ER chaperon gp96 
( fig. 1 b), indicative of the induction of ER stress. The ER 
stress induction was accompanied by decreased levels of 
PTPN2 protein ( fig. 1 c).
 ER Stress Leads to Changes in Cytokine Expression 
and Apoptosis in THP-1 Cells 
 We next investigated to what extent apoptosis and cy-
tokine expression are affected by TNM treatment in 
2 h
control
?????????????
???????????
2 h
TNM
18 h
control
18 h
TNM
a
2 h
control
gp96
???????
2 h
TNM
18 h
control
18 h
TNM
b
2 h
control
PTPN2
???????
2 h
TNM
18 h
control
18 h
TNM
c
 Fig. 1. ER stress decreases levels of PTPN2 protein in THP-1 cells. 
THP-1 cells were treated with TNM (2 μg/ml) over the indicated 
period of time to trigger ER stress. Western blots show levels of ( a ) 
phosphorylated and total eIF2α, ( b ) gp96, ( c ) PTPN2 and the load-
ing control β-actin. Experiments were performed in triplicates. 
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THP-1 cells. Therefore, we analysed the lysates (obtained 
as mentioned earlier) for poly(ADP-ribose)-polymerase 
(PARP) cleavage by Western blotting. As seen in  fig-
ure 2 a, THP-1 cells showed a strong induction of PARP 
cleavage after 18 h of TNM stimulation, a sign of apopto-
sis. To study cytokine expression, we decided to focus 
on the pro-inflammatory cytokines interleukin 6 (IL-6), 
IL-8 and tumor necrosis factor (TNF). All three cytokines 
are known to be increased in IBD patients. Furthermore, 
anti-TNF antibodies are a widely used treatment in IBD 
therapy, whereas IL-6 could also be a potential target for 
future therapeutics. IL-6 antibodies are currently used in 
clinical studies  [24] . Cell lysates were analysed by real-
time PCR and the levels of IL-6, IL-8 and TNF mRNA 
were normalised to the housekeeping gene, β-actin. IL-8 
mRNA reached a peak after 8 h of incubation (850× com-
pared to control;  fig. 2 b). The strongest TNF expression 
(250× compared to control;  fig. 2 c) was already detected 
after 2 h of TNM treatment and declined constantly 
thereafter. There was also a strong induction of IL-6 
mRNA expression after treatment for 8 and 24 h (260× 
compared to control;  fig. 2 d).
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 Fig. 2. ER stress increases apoptosis and induces expression of pro-
inflammatory cytokines in THP-1 cells. THP-1 cells were treated 
with TNM (2 μg/ml) over the indicated period of time to trigger 
ER stress.  a Western blot shows levels of uncleaved and cleaved 
PARP and the loading control β-actin. The graphs show mRNA 
levels of the pro-inflammatory cytokines ( b ) IL-8, ( c ) TNF and ( d ) 
IL-6. Experiments were performed in triplicates. Data are present-
ed as means ± SD. 
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 PTPN2 Knockdown Affects ER Stress Susceptibility in 
THP-1 Cells 
 To assess whether PTPN2 is important for regular ER 
stress responses in THP-1 cells, we knocked down 
PTPN2 using specific siRNA constructs and treated the 
cells with TNM for 18 h. Western blotting was performed 
to analyse the protein content of the cell lysates. The 
amount of detected PTPN2 protein was strongly reduced 
after transfection with PTPN2-specific siRNA compared 
to non-transfected control cells ( fig. 3 a), indicating that 
the knockdown was highly effective. In control cells, ER 
stress reduced PTPN2 protein levels ( fig.  3 a) as al-
ready  shown in previous experiments ( fig.  1 c). PTPN2 
deficiency affected phosphorylation of eIF2α under ER 
stress conditions ( fig. 3 b), as we observed an exaggerated 
induction of phospho-eIF2α in those cells. EIF2α phos-
phorylation levels in unstressed conditions were not de-
pendent on PTPN2 knockdown.
 PTPN2 Knockdown Affects Apoptosis and Cytokine 
Secretion Under ER Stress Conditions 
 As seen in the previous experiments, TNM stimula-
tion led to a strong increase in PARP cleavage ( fig. 3 c). 
In THP-1 cells with downregulated PTPN2 expression 
upon siRNA transfection, we already observed some 
PARP cleavage in un-stimulated cells. Treatment with 
TNM further increased PARP cleavage, which finally 
reached a higher level than in TNM-treated PTPN2-
competent cells. To prove that the observed increase in 
apoptosis is not secondary to the transfection procedure 
 Fig. 3. PTPN2 knockdown increases ER stress and apoptosis in 
THP-1 cells. THP-1 cells were transfected with PTPN2-specific or 
mock siRNA and treated with TNM (2 μg/ml) for 18 h. Western 
blots show levels of ( a ) PTPN2, ( b ) phosphorylated and total 
eIF2α, ( c ) uncleaved and cleaved PARP and the loading control 
β-actin. Experiments were performed in triplicates. FACS analysis 
of annexin V/PI stained cells ( d ) was used to determine level of 
apoptosis and graphs shows percentage of double positive cells ( e ). 
Experiments were done in duplicates. 
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but is a specific effect of PTPN2 knockdown, we repeated 
the experiment and used scrambled siRNA as an addi-
tional control. FACS analysis of the annexin V/PI stained 
cells showed no adverse effect of this mock control com-
pared to cells that were not transfected ( fig.  3 d, e). Fur-
thermore, this experiment confirmed the exaggerated 
apoptosis of stressed PTPN2-deficient monocytes. To 
study whether cytokine secretion is also affected by the 
knockdown of PTPN2, we performed an ELISA analysis 
to detect the pro-inflammatory cytokines TNF and IL-8. 
In control cells ER stress induction led to an increase in 
the secretion of TNF (12× induction;  fig. 4 a) and IL-8 
(40× induction;  fig.  4 b). In PTPN2 knockdown cells, 
TNM-induced secretion of both cytokines was strongly 
attenuated.
 HT-29 Intestinal Epithelial Cells Show Only Minor ER 
Stress Responses 
 To answer the question whether the observed effects 
are specific to cell type, we performed experiments using 
the intestinal epithelial cell (IECs) line HT-29. In a first 
experiment we used TNM to induce ER stress for 30 min, 
18 and 48 hours and analysed cell lysates by Western 
 blotting. TNM stimulation had only minor effects on 
PTPN2 protein levels, leading to a slight reduction visible 
mainly at the later time points ( fig. 5 a). The Western blot 
for the ER stress marker phospho-eIF2α also showed an 
induction after 48 h of TNM stimulation, whereas gp96 
protein expression did not show any obvious changes 
upon TNM treatment ( fig. 5 b, c). Enhanced PARP cleav-
age as a marker for apoptosis was observed only after 
48 h of TNM stimulation ( fig. 5 d).
 PTPN2 Knockdown is Beneficial for HT-29 Cells 
 To address the role of PTPN2 with respect to ER stress 
responses in HT-29 IECs we transfected the cells with 
PTPN2-specific siRNA. ER stress was induced by TNM 
treatment for 48 h. Cell lysates were analysed by Western 
blot, and cell culture supernatant was tested for cytokine 
secretion using ELISA.  Figure 6 a shows that PTPN2 pro-
tein levels were strongly reduced in PTPN2 siRNA trans-
fected cells, suggesting that the knockdown was effective. 
In control cells, TNM stimulation led to an increase in 
phospho-eIF2α, which was ameliorated in PTPN2 siRNA 
transfected cells ( fig. 6 b). TNM-induced PARP cleavage 
was higher in control cells than in PTPN2 siRNA-trans-
fected cells. Also, the level of cleaved PARP in untreated 
cells was reduced in PTPN2 siRNA cells compared to 
PTPN2-competent cells ( fig. 6 c). ELISA analysis showed 
that the cytokine secretion was also affected by PTPN2 
knockdown. IL-8 secretion was not changed by TNM 
treatment in HT29 IECs but was strongly reduced in cells 
featuring the PTPN2 knockdown ( fig. 6 d). The baseline 
secretion of TNF was weakly reduced after knockdown 
of PTPN2 ( fig. 6 d). Upon TNM treatment we noted a ro-
bust induction of TNF; however, it remained unaffected 
by the loss of PTPN2.
 Discussion 
 In this study we demonstrated that PTPN2 influences 
ER stress signalling in the monocytic cell line THP-1 and 
in HT29 IECs. ER stress induction using TNM resulted 
in a decline of PTPN2 protein expression in THP-1 cells, 
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thus confirming the previous data of Bettaieb et al., who 
observed the same effect in pancreatic β-cells  [20] . Con-
trary to their findings in pancreatic MIN6 cells, our study 
showed that knocking down PTPN2 in THP-1 mono-
cytes gives rise to a higher susceptibility to ER stress: 
TNM-induced phosphorylation of eIF2α, PARP cleavage 
and annexin V/PI staining were increased in PTPN2-de-
ficient cells. The TNM-induced expression of the pro-in-
flammatory cytokines TNF and IL-8 was reduced upon 
transfection with PTPN2 siRNA. This is possibly due to 
the inhibition of mRNA translation as a result of UPR ac-
tivation. Transfecting THP-1 cells with mock siRNA did 
not have any adverse effects, verifying that our observa-
tions are specific to the knockdown of PTPN2. 
 PTPN2 clearly interacts with the PERK/eIF2α pathway 
in THP-1 cells. However, we did not formally test the oth-
er two arms of the UPR. Further experiments are needed 
to see whether the other sub-pathways (via IRE1 and 
ATF6) are also influenced by PTPN2 in these cell types. 
Nevertheless, Bettaieb et al. have previously shown that 
the PTPN2-mediated effects on ER stress signalling exclu-
sively affect the PERK/eIF2alpha arm  [20] . It is nonethe-
less evident that the role of PTPN2 in ER stress signalling 
in THP-1 cells differs from that in MIN6 cells. These are 
completely different cell types and may have developed in 
distinct ways to adapt to ER stress. This could be plausible 
since there are already other proteins known to impact 
ER stress signalling in a cell type-specific manner  [25] .
 Contrary to our findings in THP-1 monocytes, we ob-
served only minor effects of ER stress on PTPN2 in the 
colonic epithelial cell line HT-29, namely a minor trend 
toward declined expression. The effect of PTPN2 defi-
ciency in HT-29 cells differed clearly from our results in 
THP-1 cells. In HT-29 cells, the knockdown of PTPN2 
had beneficial consequences: un-stimulated cells with 
PTPN2 deficiency showed less apoptosis and less secre-
tion of TNF and IL-8. This seems surprising at first glance, 
since PTPN2 has been identified as an IBD susceptibility 
gene. However, reduced levels of secreted cytokines in 
PTPN2-deficient cells might contribute to a re-balancing 
of the overwhelming immune response that can be ob-
served in IBD. It must be noted that we did not formally 
prove that altered apoptosis and cytokine secretion in 
TNM-treated cells are exclusively dependent on the in-
duction of ER stress. Therefore, there is also the possibil-
ity that these events are rather associative than causally 
linked. However, our data clearly demonstrate that these 
events are regulated by the action of PTPN2 in the setting 
of ER stress. In any way, our experiments confirm that the 
role of PTPN2 in ER stress signalling is dependent on a 
specific cell type.
 In summary, our data demonstrate that PTPN2 regu-
lates the ER stress responses in a cell type-specific man-
ner. While dysfunction of PTPN2 in monocytes might be 
associated with increased cell death, the loss of PTPN2 in 
IECs seems to protect the cells in some way. These obser-
vations might contribute to a better understanding of the 
complex role of IBD susceptibility genes in disease patho-
genesis and support the observation that PTPN2 is a cru-
cial regulator of ER stress responses.
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 Fig. 5. HT-29 cells show minor ER stress response. HT-29 cells 
were treated with TNM (2 μg/ml) over the indicated period of time 
to trigger ER stress. Western blots show levels of ( a ) PTPN2, ( b ) 
phosphorylated and total eIF2α, ( c ) uncleaved and cleaved PARP, 
( d ) gp96 and the loading control β-actin. Experiments were per-
formed in duplicates. 
 Fig. 6. PTPN2 knockdown is beneficial for HT-29 cells. HT-29 
cells were transfected with PTPN2-specific siRNA and treated with 
TNM (2 μg/ml) for 48 h. Western blots show levels of ( a ) PTPN2, 
( b ) phosphorylated and total eIF2α, ( c ) uncleaved and cleaved 
PARP and the loading control β-actin. The graphs show secretion 
of the pro-inflammatory cytokines ( d ) IL-8 and ( e ) TNF measured 
by ELISA. Data are presented as means ± SD. Experiments were 
performed in triplicates.  * Indicates p < 0.05,  * * indicates p < 0.01, 
vs.  the respective control. #  Indicates p < 0.05 vs. TNM-treated 
control siRNA transfected cells. 
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ABSTRACT 
Background/Aims: Variants in protein tyrosine phosphatase non-receptor type 
2 (PTPN2) are known to mediate susceptibility to inflammatory bowel diseases 
(IBD). Cell culture experiments suggest that PTPN2 influences barrier function, 
autophagy and secretion of pro-inflammatory cytokines. PTPN2 knockout mice 
die few weeks after birth on systemic inflammation emphasizing the importance 
of this phosphatase in inflammatory processes. The aim of this study was to 
investigate the role of PTPN2 in colon epithelial cells by performing DSS induced 
colitis in PTPN2xVilCre mice. 
Methods: Acute colitis was induced by administering 2.5 or 2.0 % DSS for 
7 days and chronic colitis by 4 cycles of treatment using 1 % DSS. The 
AOM/DSS model was used to study colon cancerogenesis. Body weight of mice 
was measured regularly and colonoscopy was done at the end of the 
experiments. Mice were sacrificed afterwards and colon specimens were 
obtained for H&E staining. 
Results: We did not observe significant influence of PTPN2 deficiency on 
histological scoring for inflammation severity after acute or chronic DSS colitis 
which was in contrast to differences found in colonoscopy or weight loss. 
Chronic colitis induced development of aberrant crypt foci more frequently in 
PTPN2flox/floxxVilCre mice compared to their PTPN2flox/flox littermates. AOM/DSS 
treatment, a model for colon cancer carcinogenesis, led to formation of aberrant 
crypts in nearly all animals irrespective of genotype. 
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Conclusions: Loss of PTPN2 in IECs has no significant influence on histological 
inflammation in DSS colitis. The difference found in colonoscopy scores and 
weight curves, however, may indicate a functional role of PTPN2 in pathways 
other than inflammation which has to be further evaluated. 
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INTRODUCTION 
Crohn’s disease (CD) and ulcerative colitis (UC) are the most common types of 
inflammatory bowel diseases (IBD), a group of chronic and relapsing 
inflammatory conditions of the intestine. Even though the multifactorial 
pathogenesis is still not entirely understood, it is generally accepted that IBD 
results from an overrated inflammatory immune response to the otherwise 
harmless, commensal microbiota in genetically predisposed individuals. 
Genome-wide association studies (GWAS) helped to identify over 160 
susceptibility loci for IBD1. Among these loci is the gene encoding protein 
tyrosine non-receptor type 2 (PTPN2) that has also been reported to be linked to 
other autoimmune diseases such as diabetes type 1 and rheumatoid arthritis2-4. 
As other phosphatases, PTPN2 is a negative regulator of many signalling 
pathways. It interferes with cytokine signalling by dephosphorylating some JAK 
and STAT molecules5-7 and participates in growth regulation and glucose 
homeostasis by targeting EGFR and insulin receptor5. PTPN2 is a ubiquitously 
expressed protein found in most mammalian embryonic and adult tissues with 
higher levels observed in lymphoid cells. In accordance with its potential role as 
IBD susceptibility gene, PTPN2 expression was found to be increased in 
intestinal biopsies of CD patients and to a lower extent also in UC patients8. 
Global loss of PTPN2 is lethal: PTPN2-/- knockout mice show defects in 
haematopoiesis, anaemia, massive tissue infiltration by mononuclear cells and 
die few weeks after birth9, 10. The embryonic development of these mice seems 
normal, the new-borns are of normal size and health. Nevertheless, at the age of 
three weeks, they are obviously smaller compared to their wild type littermates 
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and exhibit hunching, closed eyes, decreased mobility and diarrhea followed by 
death9. 
From cell culture experiments using intestinal epithelial cell (IEC) lines it is 
already known that PTPN2 expression is increased by the pro-inflammatory 
cytokines TNF and IFNγ8, 11, 12. Knockdown of PTPN2 potentiates the stimulatory 
effects of TNF and IFNγ leading to exaggerated epithelial permeability and 
amplified secretion of interleukin 6 (IL-6) and interleukin 8 (IL-8)8, 11, 12. PTPN2 
also regulates autophagy: loss of PTPN2 leads to impaired autophagosome 
formation and dysfunctional autophagy in IECs13. Without functional autophagy 
IECs are more prone to infection by intracellular invaders like listeria 
monocytogenes13. 
The above mentioned in vitro findings show the importance of PTPN2 in IECs 
and the knockout mouse demonstrates that PTPN2 also plays a role in 
inflammatory processes in vivo. Therefore, the investigation of the role of PTPN2 
in the intestinal epithelium in vivo was a promising approach. To do so, we 
generated a mouse strain with a tissue specific loss of PTPN2 in IECs. The mice 
carry loxP sequences flanking exon 3 of the PTPN2 gene and express the Cre-
recombinase under the control of the villin promotor. We used these 
PTPN2flox/floxxVilCre mice to perform acute and chronic dextran sulphate sodium 
(DSS) induced colitis. Regarding the preliminary mentioned data, we expected 
these mice to suffer from more severe colitis upon DSS treatment. 
MATERIALS AND METHODS 
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Mice and Induction of Colitis 
Animal experiments were carried out according to Swiss animal welfare laws and 
were approved by the veterinary authorities of Zurich, Switzerland (Kanton 
Zürich Gesundheitsdirektion Veterinäramt, approval no. 54/2011). Due to the 
approval of the veterinary authorities of Zurich, no further approval by an 
Institutional Animal Care and Use Committee (IACUC) or ethics committee was 
necessary. Mice were housed in a specific pathogen-free facility in individually 
ventilated cages. Food and water were available ad libitum. Female PTPN2flox/flox  
and PTPN2flox/floxVilCre littermates on a C57BL/6J background were used for all 
experiments. Mice with a bodyweight between 20 and 25 g were randomly 
divided into two DSS and two water control groups. Acute colitis was induced by 
administering 2.5 % or 2.0 % dextran sulphate sodium (DSS) (MP Biomedicals, 
Illkirch, France) dissolved in drinking water for 7 days. Chronic colitis was 
induced by four cycles of treatment with 1.5 % DSS for 7 days interspersed with 
10 days of regular drinking water and a final recovery phase of 3.5 weeks. Body 
weight and disease activity was determined regularly. At the end of the 
experiment colonoscopy was done and mice were subsequently sacrificed. 
Spleen and colon were removed, colon length and spleen weight were 
measured. Colon samples were taken for H&E staining. 
DSS/AOM Model to Study Colon Carcinogenesis 
4 cycles of DSS administration were combined with repeated intraperitoneal 
injection of azoxymethane (AOM) (Sigma) (10 µg/g). Each cycle consists of 7 
days treatment using 1.5 % DSS followed by 15 days with regular drinking water. 
AOM injections were done at day 1 of DSS treatment and day 2 of regular 
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drinking water in each cycle. After 4 cycles mice were allowed to recover for 6 
weeks. After every DSS/AOM cycle colonoscopy was performed under isofluran 
anaesthesia to screen for colon carcinogenesis and potentially end the 
experiment at an early time point if intense carcinogenesis would have been 
observed. At the end of the experiment colonoscopy was done and mice were 
sacrificed to obtain colon samples. 
Assessment of Colonoscopy Score in Mice 
Animals were anaesthetised intraperitonealy with 90-120 mg/kg body weight 
ketamine (Vétoquinol, Bern, Switzerland) and 8 mg/kg body weight xylazine 
(Bayer, Lyssach, Switzerland). Colonoscopy was performed as described 
previously14. Briefly, the solid endoscope was introduced per anus with a 
lubricant (2 % lidocaine) in the sedated mouse. The colon was gently inflated 
with air. Recording was performed with the Karl Storz Tele Pack Pal 20043020 
(Karl Storz Endoskop, Tuttlingen, Germany). Colonoscopy was scored using the 
murine endoscopic index of colitis severity (MEICS) scoring system as described 
previously85. In detail, the MEICS score was assessed as follows: The MEICS 
consists of five parameters: (1) Thickening of the colon wall (transparent, 
moderate, marked, non-transparent 0-3 points), (2) changes of the vascular 
pattern (normal, moderate, marked, bleeding 0-3 points), (3) fibrin visible (none, 
little, marked, extreme 0-3 points), (4) granularity of the mucosal surface (none, 
moderate, marked, extreme 0-3 points) and (5) stool consistency (normal solid, 
still shaped, unshaped, spread 0-3 points). This results in an overall score range 
between 0 and 15.  
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Assessment of Histological Score in Mice 
Histological scoring for inflammatory infiltration and epithelial cell damage was 
performed on H&E stained section of the most distal 1 cm of the mouse colon as 
described previously15. Score for epithelial damage: 0, normal morphology; 1, 
loss of goblet cells; 2, loss of goblet cells in large areas; 3, loss of crypts; 4, loss 
of crypts in large areas. Score for infiltration: 0, no infiltrate; 1, infiltrate around 
crypt base; 2, infiltrate reaching to L. muscularis mucosae; 3, extensive 
infiltration reaching the L. muscularis and thickening of the mucosa with 
abundant oedema; 4, infiltration of the L. submucosae. The total histological 
score represents the sum of the scores for epithelial damage and infiltration. 
Histological examination was performed by an independent, blinded investigator. 
IEC and DNA isolation from Colon Specimens  
After cutting away the most distal 3 cm of colon for other purposes, the 
remaining part of the colon was sliced lengthwise, freed from residual faeces and 
cut into small pieces. To loosen IEC, the slices were transferred to Hank’s 
balanced salt solution (HBSS; PAA, Linz, Austria) supplemented with 2 mM of 
EDTA and stirred for 30 min at 37 °C. Mucus was removed by passing the slurry 
over a coarse mesh (400 µm; Carl Roth GmbH, Karlsruhe, Germany). The sieve 
residue was flushed back to the tube with fresh HBSS, vigorously shaken 10 
times and vortexed for 1 min. The shake and vortex step was repeated twice 
resulting in 30 times shaking and 3 min of vortexing. Mucosal pieces were 
partitioned from detached cells by filtration through mesh. The flow-through was 
collected and centrifuged at 400 g for 7 min. Supernatant was discarded and the 
cell pellet was resuspended in PBS. The supernatant was removed and samples 
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were frozen in liquid nitrogen and stored at -80°C until DNA isolation. The 
pelleted IECs were defrosted and DNA was isolated using DNA Mini Kit (Qiagen, 
Düsseldorf, Germany) according to the manufacturer’s blood and body fluid spin 
protocol.  
Genotyping 
Digestion buffer (25 mM NaOH, 0.2 mM EDTA) was added to ear biopsies and 
incubated for 1 hour at 98 °C. Equal amount of neutralisation buffer (40 mM 
TrisHCl, pH 5.5) was added and 1 µl was used for genotyping VilCre PCR to 
assess the presence of the cre-recombinase. DNA isolated from IECs from colon 
specimens was used to check if cre-mediated recombination took place via 
genotyping PCR. Primer sequences VilCre PCR: VilCre_fwd: 
GTGTGGGACAGAGAACAAACC, VilCre_rev: ACATCTTCAGGTTCTGCGGG, 
Contr_fwd: CAAATGTTGCTTGTCTGGTG, Contr_rev: 
GTCAGTCGAGTGCACAGTTT; Primer sequences for PTPN2 recombinant allel: 
Primer_fwd: GCCAAGAGACAGTGGAAAGAGAG, Primer_rev: 
ACTGCAAAACCATAACTGGGC 
RESULTS 
Mice with tissue specific loss of PTPN2 in IECs 
To determine the role of the IBD susceptibility gene PTPN2 in the intestinal 
epithelium in vivo, we generated mice that exhibit a tissue specific loss of PTPN2 
in IECs (PTPN2flox/floxxVilCre mice). To address whether Cre-recombinase 
mediated recombination of the PTPN2 allele took place two PTPN2flox/flox and two 
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PTPN2flox/floxxVilCre mice were sacrificed and IECs were isolated from colon 
specimens. DNA was isolated from these IECs and used for genotyping PCR. In 
fact, Figure 1 shows that Cre-recombinase was active in PTPN2flox/floxxVilCre 
mice and mediated conversion of the PTPN2 allele in IECs. 
PTPN2flox/floxxVilCre mice tended to suffer more from acute colitis induced 
by 2.5% DSS 
The dextran sulphate sodium (DSS) induced colitis, a model of mucosal 
inflammation to study IBD pathogenesis, was used for experimental approaches. 
In a first acute colitis experiment we administered 2.5 % DSS to 
PTPN2flox/floxxVilcre mice and their PTPN2flox/flox littermates for 7 days. The DSS 
treatment induced severe weight loss in both groups (figure 2a). At the end of 
the experiment there was no significant difference in weight loss between 
genotypes but the onset of weight loss was earlier in the DSS treated 
PTPN2flox/floxxVilcre mice compared to their DSS treated PTPN2flox/flox littermates, 
leading to a significant difference at day three (figure 2a). Colonoscopy at the 
end of the experiment revealed a significant difference between the DSS groups, 
with PTPN2flox/floxxVilcre mice showing signs of more severe colon damage 
(figure 2b). DSS treatment led to a shortening of the colon in PTPN2flox/flox and 
PTPN2flox/floxxVilcre mice, but the magnitude was not influenced by PTPN2 
deficiency in IECs (figure 2c). Also, the spleen weight was increased by DSS 
induced inflammation but we did not observe a significant difference between 
both DSS treated groups (figure 2d). Histological severity of inflammation was 
scored in H&E stained colon slides with respect to infiltration and epithelial 
damage. The DSS exposure was clearly reflected by this score, but it was not 
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further exaggerated in PTPN2flox/floxxVilcre animals (figure 2e). There was a very 
severe inflammation even in the DSS treated PTPN2flox/flox group with one mouse 
reaching the maximum score of 8. Therefore, it seemed plausible that 
PTPN2flox/floxxVilcre mice did not achieve higher histological scores as severity of 
inflammation observed in the PTPN2flox/flox animals already was very high. 
Hence, we decided to lower the DSS concentration in a second acute DSS colitis 
experiment, expecting to see a more pronounced difference. 
PTPN2 deficiency in IECs did not influence inflammation in acute colitis 
induced by 2% DSS  
In a further experiment we used 2.0 % DSS for 7 days to induce acute colitis. 
The resulting weight curve is shown in figure 3a. No differences between equally 
treated groups was observed with respect to weight loss during the whole 
experiment (figure 3a).  The early onset of weight loss in the DSS treated 
PTPN2flox/floxxVilcre mice noticed upon 2.5% DSS treatment was no longer 
observed. Colonoscopy and MEICS score also did not reveal significant 
differences between genotypes (figure 3b). There was only a higher MEICS 
score in PTPN2flox/floxxVilcre animals. The DSS treatment resulted in shortening 
of the colon and increased spleen weight but the effect was independent from 
genotype (figure 3c,d). The histological score in H&E stained colon slides also 
was not affected by epithelial PTPN2 deficiency (figure 3e).  
PTPN2flox/floxxVilcre mice tended to suffer less from chronic DSS colitis 
To evaluate whether a chronic inflammation would reveal a phenotype in 
PTPN2flox/floxxVilcre mice we performed a chronic colitis experiment by four 
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cycles of DSS treatment and a final recovery phase of four weeks. No significant 
difference with respect to the weight curve was observed (figure 4a). In contrast 
to acute colitis, DSS treated PTPN2flox/floxxVilcre animals showed significantly 
less severe colitis compared to their PTPN2flox/flox littermates during colonoscopy 
(figure 4d). The difference with respect to colonoscopy findings and MEICS 
score again was not resembled by analysis of the histological score (figure 5a). 
A very similar degree of mucosal damage was found in both DSS groups. 
However, we noticed epithelial abnormalities in DSS treated PTPN2flox/floxxVilcre 
mice that were not observed during acute colitis experiments (figure 5b). Several 
aberrant crypts of different shapes formed clusters that were easily distinguished 
from the surrounding tissue. Such aberrant crypt foci are known to be a 
consequence of exposure to carcinogens and could develop into colon 
cancer16, 17. Aberrant crypt foci were observed more frequently in DSS treated 
PTPN2flox/floxxVilcre mice (figure 5b). In one mouse abnormal foci even 
penetrated the lamina muscularis and aberrant crypts were found in the 
submucosa. This could be an indicator for increased colon cancer susceptibility 
in mice that carry IEC specific PTPN2 deficiency. To address this issue we next 
performed DSS/AOM colitis, a model widely used to study colon cancer. 
PTPN2 deficiency in IECs did not affect colon carcinogenesis in DSS/AOM 
colitis 
We performed DSS/AOM colitis by administering four cycles of DSS combined 
with repeated AOM injection. Weight indicated no differences between 
genotypes (data not shown). Colonoscopy showed signs of inflammation but we 
did not detect any tumors (data not shown). The DSS induced inflammation 
SECOND MANUSCRIPT 
 
75 
resulted in a shortened colon but this was not influenced by IEC PTPN2 
deficiency (data not shown). The repeated AOM injection combined with DSS 
treatment induced aberrant crypt foci in nearly all animals irrespective of 
genotype (figure 5c).  
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DISCUSSION 
When mice were treated for seven days with 2.5% of DSS an early onset of 
weight loss in PTPN2flox/floxxVilcre mice compared to their PTPN2flox/flox 
littermates was observed and colonoscopy showed significantly worse colitis in 
those animals. When treated with 2.0% DSS for seven days these differences 
did not reoccur. In contrast, in chronic DSS colitis, mice with PTPN2 deficiency in 
IECs tended to less weight loss and colonoscopy revealed less severe colitis. 
For all conditions tested histological scoring did not indicate differences between 
genotypes with respect to epithelial damage and inflammatory infiltrates. 
Histological scoring is usually regarded as the most solid parameter in colitis 
experiments. However, the differences found in weight loss or colonoscopy point 
to the fact that there was a discrepancy between clinical features of disease and 
histology. In the context of DSS colitis epithelial specific PTPN2 deletion in IECS 
only plays a minor for the induction of the inflammatory infiltrate but may 
nevertheless have a role for overall disease severity. 
Although cell culture studies were able to show the importance of PTPN2 
expression in IECs for barrier function, secretion of pro-inflammatory cytokines 
and autophagy8, 11-13 this seems to be less relevant in vivo. DSS induced 
inflammation is mediated by the interplay of many different cells types including 
IECs and cells of the innate and adaptive immune system. When PTPN2 
function is lost in IECs this seems to influence the histological changes only 
marginally. In contrast, in vivo studies using other tissue and/or cell specific 
PTPN2 knockout mouse strains have already demonstrated the importance of 
this phosphatase for the differentiation of CD4+ cells18 but also for TCR signalling 
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and lymphopenia induced proliferation in CD8+ cells19, 20. Apparently, loss of 
PTPN2 in the T cell compartment leads to stronger phenotypes. This may be 
explained by the fact that PTPN2 is highest expressed in T cells and was first 
discovered in a screening of a human T cell cDNA library21. 
After induction of chronic colitis we detected epithelial aberrant crypt foci in the 
distal colon. This kind of epithelial transformations has been described as a 
result of exposure to carcinogens and could develop into colon cancer16, 17. 
Those abnormalities were present in most PTPN2flox/floxxVilcre animals but only 
in one PTPN2flox/flox mouse. Therefore, we considered the possibility that PTPN2 
deficiency in IECs could mediate increased susceptibility to the development of 
colon cancer. This appeared plausible since EGFR is a known target of PTPN2. 
However, our DSS/AOM colitis experiment, a common model to study colon 
carcinogenesis, did not support this assumption. The combination of DSS 
treatment and AOM injection led to the development of aberrant crypt foci in 
nearly all animals irrespective of genotype. Our experiments may indicate that 
the loss of PTPN2 in epithelial cells in PTPN2flox/floxxVilcre mice increases the 
susceptibility to aberrant crypts and dysplasia even under simple inflammatory 
conditions. These data point to a role of PTPN2 in IEC during colitis induction 
apart from simple inflammation. It may be more associated with epithelial repair. 
Further studies with different model systems will have to elucidate this IEC 
specific function. 
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FIGURES 
 
 
 
 
 
 
FIGURE 1: Conversion of the PTPN2 allele in IECs of PTPN2flox/floxxVilcre 
mice. IECs were isolated from colon specimens of PTPN2flox/floxxVilCre (ko) and 
PTPN2flox/flox (wt) mice. DNA was isolated from these IECs and used for 
genotyping PCR. Amplified PCR products were run in a 3 % agarose gel and 
100 bp DNA ladder was used to estimate amplicon lengths. 
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FIGURE 2:  PTPN2flox/floxxVilcre mice tended to exhibit more severe 
inflammation in acute colitis using 2.5 % DSS. Female PTPN2flox/floxxVilCre 
(ko) and their PTPN2flox/flox (wt) littermates received 2.5 % DSS for 7 days (n=8) 
and body weight was measured daily. (A) Percental weight changes indicate 
early onset of weight loss in PTPN2xVilCre mice, data are presented as mean ± 
SD. At day 7 colonoscopy was done and murine endoscopic index of colitis 
severity (MEICS) was used to determine inflammation severity. (B) 
Reperesentative colonoscopy pictures and MEICS show more severe DSS 
induced inflammation in PTPN2xVilCre mice. Mice were sacrificed, (C) colon 
length and (D) spleen weight was measured but both parameters were not 
influenced by genotype. Distal colon slides were used for H&E staining and 
scored for epithelial damage and infiltration. (E) Representative pictures and 
graph presenting histological score exhibit no difference between genotypes. 
Graphs B-E show values for individual mice, horizontal bars indicate mean, 
Mann Whitney U test was used for statistical analysis, * p < 0.05, ** p < 0.001 vs 
DSS treated wt group. 
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FIGURE 3:  No differences in inflammation severity in acute colitis using 2 
% DSS. Female PTPN2flox/floxxVilCre (ko) and their PTPN2flox/flox (wt) littermates 
received 2.5 % DSS for 7 days (n=4/5). Body weight was measured daily and (A) 
percental weight changes are presented as mean ± SD. At day 7 colonoscopy 
was done and murine endoscopic index of colitis severity (MEICS) was used to 
determine inflammation severity. (B) Reperesentative colonoscopy pictures and 
MEICS show no influence of PTPN2 deficiency. Mice were sacrificed, (C) colon 
length and (D) spleen weight was measured but both parameters were not 
altered by genotype. Distal colon slides were used for H&E staining and scored 
for epithelial damage and infiltration. (E) Representative pictures and graph 
presenting histological score exhibit no difference between genotypes. Graphs 
B-E show values for individual mice, horizontal bars indicate mean, Mann 
Whitney U test was used for statistical analysis. 
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FIGURE 4:  PTPN2flox/floxxVilcre mice tended to exhibit less severe 
inflammation in chronic DSS colitis. Female PTPN2flox/floxxVilCre (ko) and their 
PTPN2flox/flox (wt) littermates received 4 cycles of DSS treatment and were 
allowed to recover afterwards for 3.5 weeks (n=7/8). Body weight was measured 
regularly and (A) percental weight changes are presented as mean ± SD. 
Colonoscopy was done at the end of the experiment and murine endoscopic 
index of colitis severity (MEICS) was used to determine inflammation severity. 
(B) Reperesentative colonoscopy pictures and MEICS show less severe 
inflammation in mice with PTPN2 deficiency in IECs. Mice were sacrificed, (C) 
colon length and (D) spleen weight was measured but both parameters were not 
altered by genotype. Graphs B-D show values for individual mice, horizontal bars 
indicate mean, Mann Whitney U test was used for statistical analysis, * p < 0.05. 
 
  
SECOND MANUSCRIPT 
 
89 
  
SECOND MANUSCRIPT 
 
90 
 
FIGURE 5: PTPN2flox/floxxVilcre mice developed more frequently aberrant 
crypt foci in chronic DSS colitis but not in a DSS/AOM model for colon 
cancerogenesis. To induce chronic colitis PTPN2flox/floxxVilCre (ko) and their 
PTPN2flox/flox (wt) littermates received 4 cycles of DSS treatment and were 
allowed to recover afterwards for 3.5 weeks (n=7/8). At the end of the 
experiment mice were sacrificed and distal colon slides were used for H&E 
staining and scored for epithelial damage and infiltration. (A) Representative 
pictures and graph presenting histological score exhibit no difference between 
genotypes. Graph shows values for individual mice, horizontal bars indicate 
mean. (B) Aberrant crypt foci were detected more frequently in H&E stained 
slides of distal colon in PTPN2xVilCre mice. Colon carcinogenesis was induced 
by 4 cycles of DSS treatment combined with repeated AOM injections. (C) 
Aberrant crypt foci were found in nearly all DSS/AOM treated animal irrespective 
of genotype. 
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8 DISCUSSION 
8.1 The cell type specific role of PTPN2 in ER stress signalling 
In this work we showed that PTPN2 interferes with ER stress signalling in IECs 
and monocytes. Treatment with the ER stress inducer tuncamycin resulted in 
reduced PTPN2 protein levels in THP-1 and only slightly lowered expression in 
HT-29 cells. Bettaieb and colleagues used palmitate to create ER stress in 
pancreatic MIN6 cells and they observed impaired PTPN2 expression after 
48h63. Knockdown of PTPN2 had beneficial effects in MIN6 cells, the magnitude 
of tunicamycin or palmitate stimulated ER stress was considerably alleviated and 
fewer cells underwent ER stress mediated apoptosis.63 We observed the same 
advantageous impact of PTPN2 deficiency in HT-29 cells. In contrary, THP-1 
cells suffered from increased ER stress susceptibility that was accompanied by 
higher apoptosis rate upon PTPN2 knockdown. It should be mentioned that we 
used HT-29 cells carrying the IBD associated PTPN2 variant. Therefore, we 
cannot be sure whether the observed effects were specific for intestinal epithelial 
cells or were mediated by the mutated PTPN2 gene. Nevertheless, we clearly 
demonstrated that under ER stress conditions the role of PTPN2 varies between 
cell types. 
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8.2 PTPN2 deficiency in IECs did not influence DSS colitis 
In acute and chronic DSS colitis experiments, mice with IEC specific knockout of 
PTPN2 did not clearly differ from wild type mice. Even though colonoscopy 
indicated exaggerated inflammation in PTPN2xVilCre mice after acute colitis and 
alleviated inflammation after chronic colitis, histological analysis of colon slides 
did not resemble those differences. The histological scoring for epithelial 
damage and infiltration is regarded as the gold standard in evaluation of colitis 
severity, thereby negating the differences found during endoscopic examination. 
Hence, in IECs PTPN2 does not play an important role in inflammatory 
processes, at least not in the context of DSS induced colitis. Since global loss of 
PTPN2 is lethal and PTPN2 knockout mice die few weeks after birth on systemic 
inflammation50, we expected our PTPN2xVilCre animals to be more susceptible 
to DSS. This theory was supported by cell culture experiments that highlight the 
importance of PTPN2 in autophagy, barrier function and cytokine secretion in 
IECs54, 57, 59. Obviously, PTPN2 deficiency in IECs can be compensated by the 
organism in vivo. Therefore, the severe phenotype of mice with total loss of 
PTPN2 seems to be primary mediated by immune cells. Other mouse studies 
were able to show that PTPN2 is important for CD4+ cell development89 and for 
TCR signalling and lymphopenia induced proliferation in CD8+ cells49, 60. 
Apparently, lack of PTPN2 in the T cell compartment cannot be counterbalanced 
in vivo. 
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8.3 PTPN2 deficiency in IECS did not influence DSS/AOM colitis 
During histological analysis after chronic colitis we observed the presence of 
aberrant crypt foci more frequently in DSS treated PTPN2xVilCre mice. This kind 
of epithelial transformation is usually observed after exposition to carcinogens 
and could develop into colon cancer87, 88. This led us to the assumption tissue 
specific knockout of PTPN2 in IECs could mediate increased susceptibility to 
colorectal cancer. With EGFR among the known PTPN2 substrates this would 
perfectly make sense. An experiment using the AOM/DSS model disproved our 
theory. The combined AOM and DSS treatment induced the formation of 
aberrant crypt foci in nearly all animals irrespective of genotype. 
8.4 Concluding remarks and outlook 
In our cell culture study PTPN2 knockdown was beneficial for HT-29 cell under 
ER stress conditions. Further experiments with another IEC cell line could clarify 
whether this observed effect is IEC specific or not. We used HT-29 cells that 
carry the IBD associated SNP and therefore we cannot exclude the possibility 
that our experiments were influenced by this mutation. We did not expect the 
observed alleviation of ER stress susceptibility upon PTPN2 knockdown 
because this would be contrary to the task of a risk gene. Even though lack of 
PTPN2 in IECs is reportedly disadvantageous for autophagy57, barrier function54 
and cytokine secretion59, it is still possible that it may be beneficial in other 
pathways. 
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In the context of DSS colitis the tissue specific loss of PTPN2 in IECs did not 
influence inflammation. It would be interesting to use our PTPN2xVilCre mouse 
in another colitis model, maybe breeding into IL-10-/- background could reveal a 
phenotype. 
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